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Abstract 
Transforming growth factor-beta 1 (TGF-β1) modulates regeneration after injury through 
induction of fibroblast proliferation, migration, and differentiation into myofibroblasts. 
Induction of myofibroblast differentiation by TGF-β1 requires expression of integrin-linked 
kinase (ILK). I now show that ILK interacts with TGF-β receptor type II (TβRII) in primary 
dermal fibroblasts. Further, colocalization of ILK and TβRII can be observed at the cell 
membrane and in intracellular vesicles. The association of TβRII and ILK does not require 
TGF-β1 stimulation, kinase activity of TGF-β1 receptor type I or TβRII, and it does not 
involve interactions between ILK and focal adhesion-associated proteins. When this 
interaction is abolished by targeted inactivation of the Ilk gene, TβR signalling is diminished, 
as demonstrated by decreased phosphorylated SMAD2 levels in response to TGF-β1 
treatment. This can be restored by exogenous expression of human ILK or by inhibition of 
TβRII degradatory pathway. Thus, ILK is essential for normal TβR signalling. 
Keywords
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Chapter 1 – Introduction 
1.1 Transforming growth factor-beta 
The transforming growth factor beta (TGF-β) signalling pathway is involved in myriad 
biological, developmental, and pathological processes. The three mammalian isoforms of 
TGF-β (TGF-β1, 2, and 3) are implicated in embryonic development, tumour formation, 
hematopoiesis, regulation of the immune response, fibrosis, and wound healing (reviewed 
in Prud’homme & Piccirillo 2000). At the cellular level, TGF-β regulates proliferation 
and differentiation of diverse cell types (reviewed in Wahl 1994). However, the functions 
of these three cytokine isoforms do not completely overlap in vivo, as gene-inactivation 
studies have shown (reviewed in Dünker & Krieglstein 2000).  
1.1.1 Transforming growth factor-β1 
Transforming growth factor-β1 is a member of the TGF-β superfamily, which is 
characterized by the presence of a cysteine-knot structure. TGF-β1 is secreted as an 
inactive homodimer, which consists of a TGF-β dimer associated with the N-terminal 
latency-associated peptide (LAP). This is termed small latent complex (SLC). In the SLC, 
TGF-β and LAP are non-covalently linked. The SLC binds to latent TGF-β binding 
protein (LTBP) via disulfide bonds, forming the large latent complex (LLC). Association 
with LTBP is crucial for the incorporation of TGF-β into the extracellular matrix (ECM) 
(Miyazono K et al. 1991). In the ECM, the LLC can be cleaved by integrin αvβ6, matrix 
metalloproteinases, and/or low pH levels, to form the active TGF-β1 homodimer, which 
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can then interact with and activate TGF-β receptors on the cell surface (Münger et al. 
1999, Yu & Stamenkovic 2000, Pircher et al. 1986) (Figure 1.1). 
1.2 Wound healing 
The skin protects the body against harmful environmental agents and possesses an 
exceptional capacity for tissue and regeneration after injury. Upon cutaneous injury, 
TGF-β1 is released into the wound site to initiate wound healing (reviewed in Hinz 
2007). 
The skin is composed by two main layers: the epidermis and the dermis. The epidermis is 
a stratified squamous epithelium formed by keratinocytes at various stages of 
differentiation. The epidermis attaches to a basement membrane, which links it to the 
dermis. The latter is mainly composed of fibroblasts and various ECM substrates, 
including collagens (reviewed in Martin 1997). 
When the skin is wounded, healing processes are initiated by various growth factors and 
cytokines. Wound healing occurs through several consecutive, but overlapping phases, 
which include clot formation, inflammation, regeneration, and remodelling. 
Shortly after injury, a fibrin clot is formed to temporarily cover the wound. The clot is 
composed of fibrin fibres and platelets, which degranulate, releasing cytokines and 
growth factors. These cytokines and growth factors, including TGF-β1, act as 
chemotactic signals to attract inflammatory cells, and activate keratinocytes and 
fibroblasts adjacent to the wound. In this manner, re-epithelialization is initiated, which is 
3 
Figure 1. 1. TGF-β1 activation 
The inactive form of TGF-β1 is in complex with latency associated peptides (LAP) to 
form a small latent complex (SLC) within the cell. This associates with latent TGF-β1 
binding protein (LTBP) to form a large latent complex (LLC). The latent form of TGF-
β1is secreted by the cell and the activation of TGF-β1 requires its release from LAP, 
mediated by proteases or acidic conditions (Miyazono K et al. 1991, Yu and 
Stamenkovic 2000, Pircher et al. 1986, Finnson et al. 2013). 
LTBP
LAP
TGF-β1
LAP
LTBP
SLC
LLC
TGF-β1
LAP
LAP
LAP
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subsequently followed by tissue contraction, and angiogenesis (reviewed in Martin 1997). 
The second healing stage, which involves inflammatory responses, starts with the 
recruitment of neutrophils and monocytes to the wound site from circulating blood. These 
inflammatory cells clear the wound of contaminating microorganisms, and release pro-
inflammatory cytokines that further activate keratinocytes and fibroblasts (reviewed in 
Martin 1997). 
In the epidermis, keratinocytes are activated to proliferate and migrate during the re-
epithelialization/regeneration phase (reviewed in Singer & Clark 1999). The existing cell-
cell adhesions at the wound margins are disassembled, and new cell-ECM contacts are 
formed, via rearrangement of adhesion complexes, such as those containing integrins. 
This rearrangement assists migration of keratinocytes into the wound site. Once 
keratinocytes cover the denuded wound, re-epithelialization is complete (reviewed in 
Singer & Clark 1999). 
Dermal fibroblasts around the wound site are also activated to proliferate and migrate 
into the wound. Activated fibroblasts initially become proto-myofibroblasts. These cells 
exhibit actin stress fibres and develop limited contractile properties in response to 
mechanical stimuli and inflammation (reviewed in Tomasek et al. 2002). Growth factors, 
such as TGF-β1, together with mechanical tension, and additional signals from the ECM, 
induce differentiation of proto-myofibroblasts into myofibroblasts, characterized by 
expression of α-smooth muscle actin (α-SMA). Myofibroblasts exhibit high contractile 
properties, and thus assist in wound contraction and closure (reviewed in Tomasek et al. 
2002). 
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The last phase of healing is remodelling, during which tissue function and appearance are 
partially or completely restored. Keratinocytes differentiate to form a stratified epidermal 
layer during this phase. In the dermis, angiogenesis takes place, to form a new capillary 
network, and ECM is remodelled to reconstruct skin structures through the regulated 
synthesis and degradation of collagen (reviewed in Martin 1997). 
TGF-β1 is one of many growth factors released following cutaneous injury, and it 
promotes production of various ECM proteins, as well as wound closure. Thus, TGF-β1 
is a key modulator of tissue regeneration after wounding. This cytokine also participates 
in maintaining skin homeostasis (reviewed in Hinz 2007). 
1.3 Transforming growth factor-β receptors 
TGF-β signals are transduced by TGF-β receptors (TβR). There are three kinds of TGF-β 
receptors in mammals: Type I (TβRI), type II (TβRII), and type III (TβRIII) (reviewed in 
Shi & Massagué 2003). 
TβRII is a transmembrane serine-threonine kinase, and is thought to be constitutively 
active (Wrana et al. 1994). TβRII can be found at the cell membrane as a monomer, 
homo-oligomer, or hetero-oligomer associated with TβRI (Henis et al. 1994, Rechtman et 
al. 2009). The formation of TβRI-TβRII complexes can occur in the presence or absence 
of TGF-β1 (Henis et al. 1994, Gilboa et al. 1998, Rechtman et al. 2009). However, TGF-
β1 enhances the formation of tetraheteromeric species containing two TβRI and two 
TβRII moieties (Rechtman et al. 2009). 
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TβRI, also known as activin-linked kinase 5 (ALK5), is structurally similar to TβRII. 
However, due to its shorter extracellular domain, TβRI is unable to bind to TGF-β (Bierie 
& Moses 2006). TβRI can also be found at the cell membrane as a homodimer in the 
presence or absence of TGF-β1 (Gilboa et al. 1998, Rechtman et al. 2009). 
TβRIII, also termed betaglycan, has a short intracellular domain, and does not possess 
any known enzymatic activity. It functions to bind to TGF-β ligands and present them to 
TβRII, thus modulating this signalling pathway (Lopez-Casillas et al. 1993). 
1.3.1 Canonical TβR signalling 
The canonical TGF-β signalling pathway involves phosphorylation and activation of 
SMAD transcription factors (Miyazono et al. 2000). Canonical TβR signalling begins 
when ligand-bound TβRII transphosphorylates and activates TβRI. Active TβRI then 
phosphorylates the receptor-regulated SMAD transcription factors (SMAD2 and/or 
SMAD3). Once SMAD2 and SMAD3 are phosphorylated, they are able to recruit 
SMAD4, a common-mediator SMAD. The SMAD2/4 and/or SMAD3/4 complexes 
translocate into the nucleus, where they interact with other transcription factors and 
transcriptional regulators to increase transcription of target genes. These target genes 
include those involved in ECM remodelling, cytoskeleton organization, and acquisition 
of a contractile phenotype, such as α-SMA (reviewed in Hinz 2007). These events are 
crucial for myofibroblast differentiation and wound contraction (Figure 1.2). 
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Figure 1. 2. The canonical TGF-β1 signalling pathway 
The canonical TGF-β1 signalling pathway starts with ligand binding to TβRII, which 
recruits and activates TβRI. Activated TβRI in the TβRI-TβRII complex phosphorylates 
SMAD2/3, resulting in recruitment of SMAD4 and formation of SMAD2/4 and 
SMAD3/4 complexes. The SMAD complexes translocate to the nucleus and cause 
changes in gene transcription, such as increases in α-smooth muscle actin (α-SMA) in 
dermal fibroblasts (reviewed in Hinz 2007). 
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1.3.2 Non-canonical TβR signalling 
In addition to SMAD-mediated signalling, TGF-β also activates several non-canonical 
pathways. For example, TGF-β1 can activate Ras, Raf, and the mitogen-activated protein 
kinase (MAPK) downstream cascades, resulting in ERK stimulation. Activated ERK can 
regulate the transcription of many genes, such as type I collagen in fibroblasts (Mucsi et 
al. 1996). TGF-β1 can also activate the JNK/p38 MAPK pathway, through TGF-β-
activated kinase 1(TAK-1) stimulation (Edlund et al. 2003), leading to epithelial-to-
mesenchymal transition (EMT) and apoptosis in epithelial cells (Yu et al. 2002). 
1.3.3 TGF-β receptor endocytosis 
Following ligand binding, TβRI-TβRII complexes are internalized mainly via caveolae- 
or clathrin-mediated endocytosis (Di Guglielmo et al. 2003) (Figure 1.3). 
Caveolae-mediated endocytosis requires formation of lipid rafts (Simons & Toomre 
2000). Lipid rafts are microdomains of the plasma membrane rich in cholesterol (Simons 
& Toomre 2000). Internalization of TβRs through lipid raft/caveolin-positive vesicles 
results in the recruitment of inhibitory SMAD7 and of the SMAD ubiquitin regulatory 
factor Smurf. This recruitment, in turn, leads to ubiquitination of the receptor complex 
and its subsequent degradation by proteasomes and/or lysosomes (Kavsak et al. 2000, Di 
Guglielmo et al. 2003, Le Roy & Wrana 2005). 
In contrast, internalization of TGF-β receptor complexes via clathrin-coated pits forms 
early endosome antigen 1 (EEA-1)-positive vesicles. These vesicles become early 
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endosomes and contain complexes composed of SMAD2 and/or SMAD3 associated with 
another protein termed SMAD anchor for receptor activation (SARA) (Tsukazaki et al. 
1998). In the early endosomes, TβR complexes are sorted and subsequently directed to 
recycling endosomes. This process also results in amplification of TβR signalling 
(Runyan et al. 2005). As a next step, TβR complexes can recycle to the cell membrane or 
be targeted to late endosomes, and then to lysosomes, where they are degraded (Le Roy 
& Wrana 2005) (Figure 1.3). 
1.4 TβR signalling and skin regeneration 
TGF-β1 inhibits proliferation and DNA synthesis in epidermal keratinocytes (Matsumoto 
et al. 1990). However, it also induces expression of integrins necessary for keratinocyte 
migration and re-epithelialization (Gailit et al. 1994). 
In the wounded dermis, TGF-β1 triggers fibroblast proliferation and subsequent 
migration into the site of injury (reviewed in Hinz 2007). TGF-β1 is also necessary to 
initiate the production of a collagen-rich matrix and it induces differentiation of 
fibroblasts into myofibroblasts (Desmoulière et al. 1993, reviewed in Desmoulière et al. 
2005, Hinz 2007). If TGF-β1 signalling in mouse fibroblasts is abolished via inactivation 
of the gene that encodes TβRII, abnormal wound healing is observed. Specifically, 
decreased dermal contraction and increased rates of re-epithelialization occur under these 
conditions (Martinez-Ferrer et al. 2010). 
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Figure 1. 3. TβR complex internalization via caveolin and clathrin 
Complexes containing TGF-β and TβRs can be internalized via clathrin-dependent or 
caveolin-dependent endocytosis. TβR complexes internalized via lipid-rafts/caveolae are 
ubiquitinated and targeted for proteasomal or lysosomal degradation. TβR degradation 
can be inhibited using MG132, a proteasomal inhibitor, or nystatin, a cholesterol 
sequestering agent that inhibits formation of lipid-rafts. TβR complexes endocytosed via 
clathrin-dependent mechanisms are able to transduce further downstream signalling, and 
can be recycled back to the cell membrane, or degraded by the lysosomes (Di Guglielmo 
et al. 2003). 
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1.4.1 SMAD proteins in skin homeostasis 
Several mouse models using targeted gene inactivation or overexpression have been 
generated to determine the contribution of SMAD proteins to skin function (reviewed in 
Flanders 2004). 
For example, epidermis-restricted overexpression of SMAD2 in transgenic mice results 
in increased expression of SMAD4 and TGF-β1. These mutant mice display skin 
thickening, sparse hair, and abnormal pinna formation, due to the presence of 
hypertrophic cartilage, demonstrating the importance of proper regulation of SMAD2 
levels during development (Ito et al. 2001). Smad2 gene inactivation results in embryonic 
lethality in mice, due to impaired mesoderm formation, gastrulation, and establishment of 
the anterior-posterior axis (reviewed in Flanders 2004). In contrast, Smad3 gene 
inactivation produced mice which exhibited degenerative joint disease and chronic 
infections, due to defects in the immune system (Yang et al. 1999, Yang et al. 2001). 
Interestingly, SMAD3-deficient mice showed accelerated cutaneous wound healing, due 
to more rapid re-epithelialization and reduced accumulation of ECM in granulation tissue 
(Ashcroft et al. 1999). 
SMAD4 is the only common-mediator SMAD, and inactivation of the gene that encodes 
this protein leads to embryonic lethality due to abnormal gastrulation and endoderm 
formation (Sirard et al. 1998). Keratinocyte-specific Smad4 gene inactivation in mice, 
using a Cre-LoxP approach, showed increased basal keratinocyte proliferation, 
accompanied with increased levels of Akt phosphorylation and accelerated re-
15 
epithelization after wounding. In these animals, epidermal hyperplasia and spontaneous 
formation of skin tumours after wound repair was also reported (Yang et al. 2012, Yang 
et al. 2005, Qiao et al. 2006). Furthermore, these mice also showed progressive hair loss 
due to impaired hair follicle cycling (Yang et al. 2005, Qiao et al. 2006). 
 In vitro experiments have shown that there are two sets of TGF-β target genes: SMAD4-
dependent (e.g. SERPINE1, also known as PAI-1) and SMAD4-independent (e.g. SMAD7) 
(Levy & Hill 2005). Loss of SMAD4 expression in HaCaT cells, a spontaneously-
immortalized human keratinocyte cell line, resulted in attenuation of TGF-β1-induced 
cell cycle arrest and migration. In contrast, loss of SMAD4 expression in the pancreatic 
tumour cell line Colo-357 still led to EMT, as evidenced by the upregulation of the 
mesenchymal marker vimentin (Levy & Hill 2005). Thus, loss of SMAD4 expression 
may promote tumourigenesis by attenuation of TGF-β1-induced inhibition of 
keratinocyte proliferation without impairment of other responses to TGF-β1 involved in 
tumour progression, such as EMT (Levy & Hill 2005).  
Although SMAD2, 3, and 4 are constitutively expressed in the epidermis, the level of the 
inhibitory SMAD7 is generally low, and it increases with TGF-β1 treatment (He et al. 
2001). Keratinocyte-restricted over-expression of SMAD7 in transgenic mice resulted in 
keratinocyte proliferation, tumour progression, aberrant hair follicle morphogenesis, and 
defects in the corneal epithelium (He et al. 2002). 
Few studies have examined the effects of overexpression or gene inactivation of different 
SMAD proteins on the dermis. Overexpression of SMAD3 in fibroblasts enhances 
collagen gel contraction (an in vitro assay that mimics wound contraction) (Sumiyoshi et 
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al. 2003). Conversely, SMAD3-deficient mouse embryonic fibroblasts show diminished 
capacity for collagen gel contraction, indicating that wound contraction may be positively 
modulated by SMAD3 (Liu et al. 2003). SMAD3 deficiency also results in reduced 
fibrosis and decreased collagen deposition, due to reduced TGF-β autoinduction by 
inflammatory cells and reduced fibroblast recruitment to the wound site (Flanders et al. 
2002). Regenerated dermis from mice with Smad3 gene inactivation contained less 
myofibroblasts and scar tissue than that from normal mice, under conditions in which 
fibrosis was induced by radiation (Flanders et al. 2002). These observations signify that 
SMAD3 fulfills important pro-fibrotic functions in the skin. 
1.4.2 Pathological consequences associated with aberrant TβR 
signalling 
A large body of work has now established that insufficient or excessive TβR signalling is 
associated, respectively, with abnormal wound healing and numerous fibrotic conditions, 
including hypertrophic scarring and keloid formation in the skin (Tuan & Nichter 1998, 
Tredget 1999). For example, rats that were subcutaneously implanted with osmotic 
minipumps filled with TGF-β1 developed granulation tissue with abundant 
myofibroblasts after wounding, suggesting that TGF-β1 may play a role in scarring 
through the prolonged activation of these cells (Desmoulière et al. 1993). In keloid 
fibroblasts, high levels of TGF-β production, increased TβRI and TβRII expression, and 
elevated levels of phosphorylated SMAD3 are observed, indicating that increased TGF-β 
signalling is associated with formation of keloids and fibrosis (Chin et al. 2000). Keloid 
fibroblasts also display decreased mRNA levels of inhibitory SMADs, compared to 
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fibroblasts from non-fibrotic scars or from normal skin. In keloid fibroblasts, the low 
transcription and protein levels of inhibitory SMAD, may prolong or augment TGF-β 
signalling, contributing to the formation of excessive scarring through over-production of 
ECM (Yu et al. 2006).  
TGF-β signalling is necessary, but not sufficient, for the induction of myofibroblast 
differentiation (reviewed in Hinz 2010). Myofibroblast differentiation also requires 
mechanotransduction, that is, transduction of mechanical signals from the ECM into 
intracellular signals (reviewed in Hinz 2010) (Figure 1.4). Mechanical stimuli are 
transduced by integrins (reviewed in Hinz 2010) (Figure 1.5). In the context of the 
dermis, integrins play a role in myofibroblast differentiation by mediating the transition 
of fibroblasts to proto-myofibroblasts containing stress fibres, which subsequently 
differentiate into myofibroblasts with additional mechanical stress and with TGF-β1 
stimulation (reviewed in Hinz 2010). 
1.5 Integrins 
Integrins are a major class of cell surface proteins that participate in cell-cell and cell-
ECM communication (reviewed in Hinz 2010). There are 18 α and 8 β subunits known in 
mammalian cells, which form 24 different heterodimers composed of one α and one β 
subunit. The α subunit in each αβ dimer determines ligand-binding affinities (reviewed in 
Margadant et al. 2010). 
In intact epidermis, the most abundant integrins are α2β1, α3β1, and α6β4 (reviewed in 
Watt 2002). The expression of these integrins is confined to basal keratinocytes. Integrins 
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Figure 1. 4. Myofibroblast differentiation 
Dermal and other fibroblasts are induced to differentiate into proto-myofibroblasts by 
mechanical stimuli. Proto-myofibroblasts contain stress fibres but does not express α-
smooth muscle actin (α-SMA). With added stimulation by TGF-β1, proto-myofibroblasts 
differentiate into contractile myofibroblasts, which express α-SMA and aid in closure of 
the wound (reviewed in Hinz 2010). 
Mechanical stimulus,
TGF-β1
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Fibroblast Proto-myofibroblast Myofibroblast
19
20 
Figure 1. 5. Integrin-mediated mechanotransduction 
Heterodimeric integrins at focal adhesions transduce ECM signals into 
intracellular signals. ILK has been shown to colocalize to the focal adhesions and 
interact with various proteins (reviewed in Wickström et al. 2010a). Integrin-
mediated signal transduction and TGF-β1 stimulation are both required for 
myofibroblast differentiation.
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mediate attachment of these cells to the underlying basement membrane (reviewed in 
Watt 2002). Integrins are down-regulated in the differentiated keratinocytes of the 
suprabasal layers, and are up-regulated in motile keratinocytes at wound sites or in 
several skin disorders, including psoriasis and carcinomas (reviewed in Margadant et al. 
2010). In epidermal keratinocytes, integrins promote focal adhesion kinase (FAK) 
signalling and Rac1 activation, leading to keratinocyte spreading, polarization, and 
subsequent migration into the wound (Choma et al. 2007).  Keratinocyte-restricted 
inactivation of the Itgb1 gene, which encodes for integrin β1, results in abnormal hair 
follicle morphogenesis and severe blistering due to abnormal basement membrane 
assembly (Brakebusch et al. 2000, Raghavan et al. 2000), as well as delays in 
keratinocyte migration to wound sites (Grose et al. 2002). In addition, epidermis-
restricted β1 integrin gene inactivation results in perinatal death due to abnormal 
epidermal barrier formation, leading to dehydration (Raghavan et al. 2000). 
Integrins α1β1, α2β1, and α5β1 are expressed in dermal fibroblasts (reviewed in Silver et 
al. 2003). Myofibroblasts express those same integrins, in addition to αvβ5, αvβ3, and 
αvβ8. The latter three integrin contribute to latent TGF-β1 activation by binding to LAP 
and causing a conformational change when mechanical stimuli are applied by ECM 
stretch or cell contraction (reviewed in Hinz 2010). Integrins play important roles in focal 
adhesion formation, signal transduction, cell adhesion, and migration. The majority of 
integrin complexes link the ECM to the actin cytoskeleton, thus transducing mechanical 
stimuli (Geiger et al. 2009).  
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Integrin β1 can also play a role in activation of latent TGF-β (Liu et al. 2010). For 
example, in mink lung epithelial cells co-cultured with integrin β1-expressing fibroblasts, 
the plasminogen activator inhibitor-1 (PAI-1) promoter activity is activated (Liu et al. 
2010). PAI-1 is a TGF-β target gene. Conversely, integrin-β1-deficient fibroblasts were 
unable to induce PAI-1 promoter activation in those cells (Liu et al. 2010). Loss of β1 
integrin expression reduces myofibroblast formation and fibroblast proliferation, 
adhesion and spreading on ECM (Liu et al. 2010). Fibroblast-restricted Itgb1 gene 
inactivation leads to poor wound healing due in part, to poor α-SMA stress fibre 
formation and impaired myofibroblast differentiation (Liu et al .2010). Integrin β1 is also 
required for normal Rac1 activation and generation of reactive oxygen species in dermal 
fibroblasts, which are important for the production of type I collagen and α-SMA (Liu & 
Leask 2013, Liu et al. 2009). Other integrin heterodimers, including α11β1, αvβ1, αvβ3, 
αvβ5, αvβ6, αvβ8, α8β1, α5β1, and α3β1 have been shown to play a role in TGF-β1 
signalling during myofibroblast differentiation (Carraceodo et al. 2010, reviewed in 
Margadant & Sonnenberg 2010). 
1.6 Interactions between integrins and TGF-β1 
Given that integrins and TGF-β are required for myofibroblast differentiation, it is not 
surprising that a crosstalk exists between these two pathways. Many studies have shown 
that integrins modulate the TGF-β pathway and, reciprocally, that TGF-β can modulate 
expression and activation of integrins and integrin-associated proteins (reviewed in 
Margadant & Sonnenberg 2010). 
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The LAPs of inactive TGF-β1 complexes contain arginine-glycine-aspartic acid (RGD) 
sequences that are bound by integrin β1 (Münger et al. 1998). Integrin αvβ1 recognizes 
and binds to this sequence, which suggests a potential role for integrin αvβ1 in 
modulating the localization of TGF-β1 at the cell surface (Münger et al. 1998). Other 
studies have shown a significant role for integrin complexes in the modulation of TGF-β1 
activation and, indirectly, by regulating the expression of TβRI, TβRII, and SMAD7 
(reviewed in Margadant & Sonnenberg 2010). For example, integrin α3-deficient mice 
show increased SMAD7 expression, along with decreased pSMAD2 levels and delayed 
re-epithelialization, indicating that integrin α3 plays an important role in regulating TβR 
signalling (Reynolds et al. 2008).  
Integrin αvβ6 expression increases in epidermal keratinocytes at wound edges (Breuss et 
al. 1995). Integrins αvβ6 and αvβ8 bind to latent TGF-β1, by interacting with LAP, and 
they also activate TGF-β1 in lung epithelial cells (Münger et al. 1999, Mu et al. 2002). 
When the RGD amino acid sequence in LAP is mutated to RGE, integrins αvβ6 and αvβ8 
cannot bind to the latent form of this mutant TGF-β1, resulting in attenuated integrin-
mediated TGF-β1 activation. Mice that express this mutant exhibit phenotypes similar to 
those of TGF-β1-null mice (Yang et al. 2007). 
Interestingly, although integrin β3-null mice show decreased keratinocyte proliferation, 
they also exhibit enhanced wound healing rates because of enhanced infiltration of 
dermal fibroblasts into the wound site (Reynolds et al. 2005). Elevated levels of TGF-β1, 
TβRI and TβRII are observed in integrin β3-null mice, resulting in enhanced TGF-β1 
signalling and wound closure rates. This finding suggests that TGF-β1 signalling is 
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suppressed by αvβ3 integrins. Finally, induction of suprabasal epidermal expression of 
integrin α6β4, which is normally localized to basal keratinocytes, also results in aberrant 
TGF-β1 signalling, leading to abrogation of TGF-β-mediated growth inhibition (Owens 
et al. 2003).  
TGF-β can modulate the expression of various types of integrins. For example, TGF-β1 
stimulation in epidermal keratinocytes leads to increased expressions of α5β1, αvβ4, and 
α2β1 integrins, decreased expression of α3β1 integrin, and de novo expression of αvβ6 
integrin, all of which are similar to integrin expression patterns at the wound edge 
(Zambruno et al. 1995). 
In fibroblasts, integrin αvβ5 has been shown to promote myofibroblast differentiation by 
stimulating TGF-β1 autocrine signalling (Asano et al. 2006a, b). Fibroblast-restricted loss 
of integrin β1 also leads to reduced activation of TGF-β1, resulting in delayed wound 
healing (Liu et al. 2010). This evidence shows that under abnormal skin conditions, 
including wounded skin, integrin expression is altered, leading to changes in TGF-β 
signalling. Consistent with this concept, pharmacological inhibition of TGF-β1 signalling 
in mouse embryo fibroblasts interfered with α11 integrin up-regulation in response to 
mechanical strain (Carracedo et al. 2010). These observations suggest that, without TGF-
β1 signalling, mechanical stimuli cannot be properly transduced. In addition, fibroblast-
specific inactivation of the Tgfbr2 gene resulted in reduced levels of α1, α2, and β1 
integrins (Martinez-Ferrer et al. 2010).  
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1.7 Integrin-linked kinase (ILK) 
Integrins do not have catalytic activity and signals generated by their activation are 
transduced by various proteins that bind to their cytoplasmic domains. These proteins 
include FAK and integrin-linked kinase (ILK) (reviewed in Margadant et al. 2010). 
Integrin-linked kinase was first described as a serine-threonine kinase, which binds 
directly to β1 integrins to transduce ECM signals (Hannigan et al. 1996). It is a 
ubiquitous pseudokinase with scaffolding properties and an apparent molecular weight of 
51 kDa (Fukuda et al. 2011). ILK contains three main domains: five N-terminal ankyrin 
repeats, a pleckstrin-homology-like domain, and a C-terminal kinase-like domain (Figure 
1.6) (Chiswell et al. 2008). 
The ankyrin repeat region is responsible for its interaction with Particularly Interesting 
New Cysteine-Histidine protein (PINCH) (Tu et al. 1999, Chiswell et al. 2008). The 
central region resembles a pleckstrin-homology domain, based on its amino acid 
sequence, but is unable to bind phosphatidylinositol 3,4,5-trisphosphate (Fukuda et al. 
2009). The kinase-like domain at the C-terminus interacts with paxillin and α-, β-, and γ-
parvins (reviewed in Qin & Wu 2012). The interaction between ILK and α-parvin occurs 
at focal adhesions, and regulates cell adhesion and actin cytoskeleton organization (Tu et 
al. 2001). ILK colocalizes with β-parvin, also known as affixin, at focal adhesions, and 
they regulate cell adhesion (Yamaji et al. 2001). Lastly, γ-parvins, which are expressed in 
hematopoietic cell types, interact with ILK, although the biological significance of this 
interaction is still unclear (Chu et al. 2006).  
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Figure 1. 6. ILK protein domains 
ILK has 452 amino acids and three distinct domains, based on sequence homology. The 
first N-terminal 174 amino acids include 5 ankyrin repeats. Amino acid residues 180-212 
form a pleckstrin homology-like domain (PH), and amino acid residuces 193-447 exhibit 
some homology to protein kinases (Chiswell et al. 2008). 
N-terminus C-terminus
Ankyrin repeats
PH Pseudokinase1 2 3 4 5
1 452
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1.7.1 ILK as a pseudokinase 
There are numerous reports providing evidence for and against the idea that ILK 
possesses kinase activity. 
The amino acid sequence of ILK shows a fairly large degree of homology to 
serine/threonine kinases. The kinase domain of ILK possesses ATP-binding lysine 
residue and an APE motif, which are conserved residues in other serine-threonine kinases. 
Mutation of the ATP-binding lysine has been associated with decreased enzymatic 
activity (Maydan et al. 2010). Although ILK lacks other motifs conserved in kinases, 
such as DFG and HRD motifs, not all kinases possess them. For example, 
calcium/calmodulin-dependent serine protein kinase (CASK) lacks the canonical DFG 
motif, which is indispensable for kinase function, as it is required for Mg2+ binding, and 
yet CASK can phosphorylate its substrates without Mg2+ (Mukherjee et al. 2008). Haspin, 
another protein kinase, also lacks in DFG and APE motifs, but is still catalytically 
functional (Eswaran et al. 2009). 
It has been reported that ILK can phosphorylate myelin basic protein, and the 
cytoplasmic domain of β1 integrin (Hannigan et al. 1996), β-parvin (affixin) (Yamaji et al. 
2001), 17 kDa protein kinase C-dependent phosphatase inhibitor, and phosphatase 
homoenzyme inhibitor-1 in vitro (Deng et al. 2002). In addition, purified ILK was 
reported to directly phosphorylate protein kinase B (PKB/Akt) (Persad et al. 2001). A 
point mutant ILK E359K showed suppressed kinase activity in some, but not other 
studies (Persad et al. 2001). 
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More recently, a thorough study was conducted to determine whether ILK is a bona fide 
kinase (Maydan et al. 2010).   In this study, highly purified recombinant glutathione S-
transferase (GST)-ILK was reportedly isolated and purified from insect cells with no 
detectable contaminating kinases, as shown by mass spectrometric analysis. The purified 
GST-ILK showed autophosphorylation and phosphorylation of the 20-kDa regulatory 
myosin light chain, as well as glycogen synthase kinase-3 peptide in a Mn2+-dependent 
manner, with phosphorylation kinetics reportedly comparable to other kinases (Maydan 
et al. 2010). In this study, no data on Akt phosphorylation were included. Together, all 
these observations have led several groups to propose that ILK is a bona fide serine-
threonine kinase. 
On the other hand, ILK lacks many key motifs that are conserved in other kinases. There 
are three conserved motifs: a VAIK motif to orient ATP in the ATP-binding pocket, an 
HRD motif for proton transfer, and a DFG motif to bind Mg2+ and for alignment of β- 
and γ-phosphates of ATP in the ATP-binding pocket (Boudeau et al. 2006). ILK does not 
possess DFG and HRD motifs, and although ILK binds to ATP, it cannot hydrolyze it to 
ADP, since the putative catalytic loop of ILK is distant from the bound ATP (Fukuda et 
al. 2009). 
Other in vitro studies have shown that purified recombinant ILK is unable to 
phosphorylate previously identified substrates, including myelin basic protein and 
cytoplasmic tail of β integrin (Fukuda et al. 2009). It has also been shown that ILK 
deficiency or expression of mutant ILK lacking its “kinase” activity (ILK E359K) has 
negligible effects on phosphorylation of its proposed substrates, such as PKB/Akt and 
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GSK-3β in many cell types. For example, ILK-deficient immortalized kidney fibroblasts 
show lack of cell spreading, focal adhesion formation, and stress fibre formation, which 
can be restored by ILK E359K (Sakai et al. 2003), suggesting that the “kinase” activity of 
ILK either does not exist, or that it is dispensable. These cells also show comparable 
levels of PKB/Akt and GSK-3β phosphorylation to those observed in ILK-expressing 
cells (Sakai et al. 2003). Similarly, ILK-deficient chondrocytes show defects in cell 
adhesion, spreading, focal adhesions, and stress fibre formation, indicative of its role in 
actin organization. In these cells, PKB/Akt and GSK-3β phosphorylation was unaffected 
(Grashoff et al. 2003). In vitro kinase assays using ILK E359K immunoprecipitates from 
HeLa cells show comparable kinase activity to those of wild-type ILK 
immunoprecipitates (Nikolopoulos & Turner 2002). 
In vivo experiments have also shown that an intact “kinase” domain in ILK is dispensable 
for normal function. In Drosophila melanogaster, embryos that expressed ILK E359K 
showed similar phenotypes to those that expressed wild-type ILK. In this system, human 
ILK E359K rescued embryonic lethality caused by the lack of functional endogenous 
ILK (Zervas et al. 2001). In Caenorhabditis elegans, abnormal muscle assembly in the 
absence of ILK was restored by introduction of human ILK E359K, indicative of the 
dispensable “kinase” activity of ILK in vivo (Mackinnon et al. 2002). 
In a very elegant study, Lange et al. generated several knock-in mouse strains with point 
mutations in the Ilk gene that had previously been reported to affect kinase activity in 
vitro (Lange et al. 2009). Mice expressing ILK S343A, previously shown by other groups 
to lack kinase activity in in vitro kinase assays, or ILK S343D, shown to exhibit 
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hyperactive kinase function, displayed a normal phenotype. This indicates that the 
proposed kinase activity of ILK observed in in vitro studies is not required for normal 
development (Lange et al. 2009). Epidermal keratinocytes from these mice showed 
normal adhesion, spreading, actin cytoskeleton formation, and focal adhesion formation 
(Lange et al. 2009). In addition, phosphorylation of previously identified substrates of 
ILK – Akt1 and Gsk3β – was not affected in vivo by expression of these ILK mutants 
(Lange et al. 2009). Mice expressing other ILK mutants previously reported to lack 
kinase activity, including ILK K220A or ILK K220M, displayed normal skin phenotypes 
and phosphorylation of Akt1 and Gsk3β, contrary to previous reports (Lange et al. 2009). 
These observations are consistent with the notion that ILK is a pseudokinase. 
1.7.2 ILK as a scaffold protein 
ILK fulfills important biological functions through its scaffolding properties. For 
example, mutation of E359 to K abrogates the interaction between ILK and α-parvin or 
paxillin. This ILK mutant cannot localize to focal adhesions and interferes with cell 
adhesion and migration (Wu & Dedhar 2001, Nikolopoulos & Turner 2002). Knock-in 
mice expressing ILK K220A exhibited renal agenesis, similar to that observed in α-
parvin-deficient mice (Lange et al. 2009). Upon further examination of ILK K220A, it 
was discovered that the interaction between ILK K220A and α-parvin was significantly 
decreased relative to wild-type ILK, which likely caused severe impairment in kidney 
development (Lange et al. 2009). Others have also shown that ILK K220M causes 
impaired kidney development owing to its disrupted structural integrity (Fukuda et al. 
2011). ILK also functions as an adaptor protein in complexes with PINCH and parvin at 
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focal adhesions, to transduce ECM signals (Tu et al. 1999, reviewed in Wickström et al. 
2010a). 
1.7.3 ILK and its role in the skin 
Integrin-linked kinase plays a role in cell growth, differentiation, motility, and attachment 
(reviewed in McDonald et al. 2008). As a scaffold, ILK serves as a linker between 
integrins and the actin cytoskeleton (Wu & Dedhar 2001; Blumbach et al. 2010). ILK 
expression is essential during embryogenesis, as ILK-null embryos fail to implant, due to 
impaired actin cytoskeleton organization and polarization (Sakai et al. 2003). 
Additionally, ILK modulates front-rear cell polarity, adhesion and migration of epidermal 
keratinocyte, and it is required for hair follicle morphogenesis (Lorenz et al. 2007, 
Nakrieko et al. 2008a). ILK forms a complex with engulfment and cell motility 2 
(ELMO2) and RhoG, and this complex mediates EGF-induced keratinocyte polarization 
(Ho et al. 2009, Ho & Dagnino 2012). ILK-deficient keratinocytes also display reduced 
levels of active Rac1 when stimulated to migrate, which is crucial for the formation of a 
leading edge in motile cells (Nakrieko et al. 2008a). This underlines the importance of 
ILK in wound healing. Mice with targeted inactivation of the Ilk gene in the epidermis 
have fragile skin, blisters, abnormal hair follicles, and epidermal detachment from the 
basement membrane (Nakrieko et al. 2008a, Lorenz et al. 2007). Targeted Ilk gene 
inactivation in keratin-15-expressing keratinocyte hair follicle stem cells resulted in 
altered wound healing, due to delayed re-epithelialization (Nakrieko et al. 2011). 
Fibroblast-restricted Ilk gene inactivation leads to decreased myofibroblast differentiation 
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in vitro and in vivo, and number of myofibroblasts at the wound site in vivo, ultimately 
resulting in reduced wound closure rates (Blumbach et al. 2010, Vi et al. 2011). 
1.8 Rationale and hypothesis 
Our laboratory has previously demonstrated that ILK is abundant throughout the dermis 
(Nakrieko et al. 2008a) and is required for normal TGF-β1-induced dermal myofibroblast 
differentiation in culture (Vi et al. 2011). ILK-deficient dermal fibroblasts display 
decreased α-SMA expression and SMAD2 phosphorylation in response to TGF-β1 
stimulation (Vi et al. 2011). These observations suggest a key modulatory role for ILK in 
TβR signalling and for proper wound healing. Moreover, dermis-restricted Ilk gene 
inactivation in mice results in abnormal healing of full-thickness wounds due to reduced 
levels of TGF-β1, impaired myofibroblast differentiation, and reduced number of 
myofibroblasts in the wound (Blumbach et al. 2010). ILK-deficient fibroblasts also show 
impaired cell migration due in part, to increased activity of RhoA, which is associated 
with cell contractility, and accompanying decrease in active Rac1 (Vi et al. 2011, 
Blumbach et al. 2010). In addition, ILK interacts with various proteins for mediating 
signal transduction and it possesses multiple protein-protein interaction domains. 
The above observations led me to hypothesize that ILK interacts with TβRII and 
promotes TβR signalling. To test this hypothesis, my specific objectives were: 
1. To investigate if ILK and TβRII associate in protein complexes.
2. To determine if ILK modulates signalling and /or turnover of TβR.
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Chapter 2 – Materials and Methods 
2.1 Reagents and materials 
Reagents and their sources are as follows: 
Table 1: Reagents and materials 
Reagents and materials Source Catalogue number 
HyQ-Dulbecco’s Modified Eagle 
Medium-Reduced Serum (HyQ-DMEM-
RS) 
Hyclone/Thermo 
Scientific, Logan, UT SH3056501 
Fetal bovine serum (FBS) Gibco, Burlington, ON 12483 
0.25% trypsin with
ethylenediaminetetraacetic acid (EDTA) Gibco, Burlington, ON 25200-056 
Ca2+-free Eagle’s minimum essential 
medium (EMEM) Lonza, Walkersville, MD 06-174G 
FBS for keratinocytes Lonza, Walkersville, MD 14-561F 
Chelex 100 chelating resin (sodium form, 
200–400 dry mesh size) 
Bio-Rad, Mississauga, 
ON 142-2842 
Penicillin and streptomycin solution 
(10000 U/ml penicillin and 10000 μg/ml 
streptomycin) 
Gibco, Burlington, ON 15140 
Hydrocortisone Sigma, St. Louis, MO H4001 
Insulin Sigma, St. Louis, MO I6634 
Cholera toxin 
List Biological 
Laboratories Inc, 
Burlington, ON 
100 
Epidermal growth factor (EGF) Sigma, St. Louis, MO E4127 
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Triiodothyronine Sigma, St. Louis, MO T6397 
2.5% trypsin Gibco, Burlington, ON 15090-046 
Type I collagenase Worthington, Lakewood, NJ LS004196 
Polyethyleneimine (PEI, 25 kDa linear) Polysciences, Warrington, PA 23966 
PrimariaTM culture dishes BD, Mississauga, ON CA25482-701 
24-well FalconTM cell culture plates BD, Mississauga, ON 353226 
15-ml FalconTM conical tubes BD, Mississauga, ON 352097 
50-ml FalconTM conical tubes BD, Mississauga, ON 352098 
70-μm pore size FalconTM cell strainer BD, Mississauga, ON 352350 
100-μm pore size FalconTM cell strainer BD, Mississauga, ON 352360 
Phospho Safe extraction reagent Novagen, San Diego, CA 71296-3 
Phenylmethylsulfonylfluoride (PMSF) Bioshop, Burlington, ON PMS123 
Na3VO4 BioShop, Burlington, ON SOV664 
NaF Sigma, St. Louis, MO S7920 
Aprotinin BioShop, Burlington, ON APR200 
Pepstatin BioShop, Burlington, ON PEP605 
Leupeptin BioShop, Burlington, ON LEU001 
Bradford protein quantification solution Bio-Rad, Mississauga, ON 500-0006 
Pierce protein A/G magnetic beads Thermo Scientific, Burlington, ON 88803 
Dithiothreitol (DTT) BioShop, Burlington, ON DTT001 
Polyvinylidene fluoride membranes 
(PVDF) Millipore, Billerica, MA IPVH00010 
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Amersham ECL Prime Western blotting 
detection reagent 
GE Healthcare, 
Mississauga, ON RPN2232 
UltraCruz autoradiography film 
Santa Cruz 
Biotechnology, Santa 
Cruz, CA 
SC-201697 
Rat tail collagen I BD Biosciences, Bedford, MA 354236 
Paraformaldehyde (PFA) Fisher Scientific, Whitby, ON AC416780030 
Triton X-100 EMD, Darmstadt, Germany CATX 1568 
Hoechst 33342 Life Technologies, Burlington, ON H1399 
Immu-mount mounting medium Thermo Scientific, Pittsburgh, PA 9990402 
Recombinant human transforming growth 
factor-beta 1 (TGF-β1) Peprotech, Rocky Hill, NJ 100-21 
SB431542 Sigma, St. Louis, MO 54317-5MG 
Nystatin Sigma, St. Louis, MO N4014 
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2.2 Antibodies 
Antibodies and their sources are as follows: 
Table 2: Antibodies 
Antibodies Source Catalogue number 
Anti-HA (Y-11) Santa Cruz Biotechnology, Santa Cruz, CA SC-805 
Anti-type II TGF-β receptor (TβRII, 
C-16) 
Santa Cruz Biotechnology, Santa 
Cruz, CA SC-220 
Mouse monoclonal anti-ILK BD Transduction Laboratories, Lexington, KY 611802 
Anti-γ-tubulin Sigma, St. Louis, MO T6557 
Anti-V5 Invitrogen, Carlsbad, CA R960.25 
Anti-Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) Assay Designs, Ann Arbor, MI CSA-335 
Anti-phosphorylated SMAD2 
(pSMAD2) 
Chemicon/Millipore, Temecula, 
CA AV3849 
Anti-SMAD2/3 BD, Mississauga, ON 610842 
HRP-conjugated goat anti-mouse 
IgG 
Jackson ImmunoResearch, West 
Grove, PA 115-038-003 
HRP-conjugated goat anti-rabbit IgG Cell Signalling, Pickering, ON 7074 
AlexaFluor™ 594 -conjugated goat 
anti-mouse IgG 
Molecular Probes/Invitrogen, 
Eugene, OR A11005 
AlexaFluor™ 488-conjugated goat 
anti-rabbit IgG 
Molecular Probes/Invitrogen, 
Eugene, OR A11008 
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The hybridoma cells that produce E7 anti-β-tubulin antibody developed by M. 
Klymkowsky were obtained from the Developmental Studies Hybridoma Bank 
developed under the auspices of NICHD and maintained by The University of Iowa 
(Department of Biology, Iowa City, IA 52242). For production of anti-β-tubulin 
antibodies, hybridoma cells were cultured in RPMI-1640 medium (Gibco, Burlington, 
ON, 22400) supplemented with 10% FBS, 0.01M 2-mercaptoethanol, 1% non-essential 
amino acids (Gibco, Burlington, ON, 11140), and 50 μg/ml gentamicin (Gibco, 
Burlington, ON, 151710-064). Cells were cultured at 37°C in a humidified atmosphere 
containing 5% CO2 until the growth medium had turned yellow and most of the cells had 
lifted off the culture flask (2-3 days). The culture medium containing the β-tubulin 
monoclonal antibody was collected and centrifuged at 1000 x g, 4°C for 10 minutes to 
remove cells and cell debris. The supernatant was collected and stored at -20°C. 
2.3 Cell isolation and culture 
2.3.1 Immortalized mouse dermal fibroblasts 
Immortalized mouse dermal fibroblasts (IMDF) are a spontaneously immortalized line of 
dermal fibroblasts originally isolated from 2-days-old CD-1 mice (Apostolova et al. 
2002). They were cultured in HyQ-DMEM-RS, supplemented with 8% FBS at 37°C in a 
humidified atmosphere containing 5% CO2. All experiments were conducted with cells 
that had reached ≤ 80% confluence and that had been passaged for 15 generations or less. 
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2.3.2 Primary mouse epidermal keratinocytes 
Epidermal keratinocytes were isolated from Ilktm1Star mice, in which exons 5 to 12 of both 
Ilk alleles are flanked by loxP sequences (hereafter termed Ilkf/f mice) (Terpstra et al. 
2003). These mice were sacrificed at 3-days of age by CO2 inhalation, their skin was 
harvested, and epidermal keratinocytes were isolated and cultured as previously 
described (Ho et al. 2009, Dagnino et al. 2010). Briefly, after euthanasia, mice were 
immersed in 70% ethanol for 10 minutes at 4°C, to sterilize the skin. The skin was then 
removed and was floated, dermis side down, in freshly diluted 0.25% trypsin, for 16 
hours at 4°C. The trypsin was removed by aspiration, and replaced with fresh 0.25% 
trypsin and incubated at 37°C for 15-30 minutes. The epidermis was mechanically 
separated from the dermis. The dermis was processed separately to isolate fibroblasts, as 
described in section 2.3.3. The epidermis was minced with scissors and placed in 
keratinocyte growth medium (Ca2+-free EMEM supplemented with 8% Chelex resin-
treated FBS, 100U/ml penicillin, 100μg/ml streptomycin, 74 ng/ml hydrocortisone, 5 
μg/ml insulin, 9.5 ng/ml cholera toxin, 5 ng/ml EGF, and 6.7 ng/ml triiodothyronine). 
The minced tissues were incubated at 37°C for 20 minutes, with gentle rocking, to obtain 
a single-cell suspension. The latter was then filtered through a 70-μm cell strainer to 
remove tissue fragments. The cells were plated onto PrimariaTM culture dishes at a 
density of 1 x 105 cells/cm2. The following day, the growth medium was replaced, and 
medium changes were conducted every other day thereafter. Keratinocytes were cultured 
at 37°C in a humidified atmosphere containing 5% CO2. All experiments were conducted 
on keratinocytes that had reached ≤ 80% confluence, and that had been cultured 2-3 days. 
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2.3.3 Primary mouse dermal fibroblasts 
Primary fibroblasts were isolated from the dermis of 3 days-old Ilkf/f mice (Terpstra et al. 
2003). Dermal tissues obtained following mechanical separation from the epidermis 
(section 2.3.2.) were minced with scissors and incubated in a solution containing 0.35% 
w/v Type I collagenase, diluted in HyQ-DMEM-RS and supplemented with 100U/ml 
penicillin and 100μg/ml streptomycin. The minced tissues were incubated at 37°C for 30 
minutes with gentle rocking. An equal volume of dermal fibroblast growth medium 
(HyQ-DMEM-RS supplemented with 8% FBS, 100U/ml penicillin, and 100μg/ml 
streptomycin) was added and the cell suspension was then filtered through a 100-μm cell 
strainer. The cells in the filtered suspension were centrifuged at 200 x g at 22°C for 5 
minutes, resuspended in fibroblast growth medium, and plated onto culture dishes at a 
density of 2.5 x 104 cells/cm2. Dermal fibroblasts were cultured at 37°C in a humidified 
atmosphere containing 5% CO2. All experiments were conducted on cells that had 
reached ≤ 80% confluence and that had not been passaged more than 4 times. 
2.4 Transient transfections 
Primary keratinocytes and IMDF cells were transiently transfected with vectors encoding 
V5-tagged wild-type and mutant ILK and/or with vectors encoding HA-tagged wild-type 
and mutant TβRII (Figure 2.1) using PEI as previously described (Dagnino et al. 2010). 
A PEI stock solution of 1 mg/ml was prepared by dissolving PEI in 18 MΩ water with 
constant stirring, and adjusted to pH 7.0 with HCl. The solution was then sterilized 
through a 0.22-μm filter and stored in aliquots at -20°C. For a 10-cm culture dish, 3.5-9 
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μg of total DNA (1 μg/μl stock), 60 μl of 1 mg/ml PEI solution, and sterile 150 mM NaCl 
were combined to make a total volume of 500 μl. For a well of a 24-well culture plate, 
the transfection solution contained 2 μg of total DNA (1 μg/μl stock), 6 μl of 1mg/ml PEI 
solution, and 92 μl of sterile 150 mM NaCl. The transfection solution was mixed by 
vortexing and incubated at 22°C for 10 minutes. Transfection solutions were added 
dropwise to the growth medium in individual culture dishes and thoroughly mixed. The 
cells were cultured in the presence of the transfection solution for 4 hours. The medium 
was then replaced with fresh culture medium, and the cells were cultured for 24-48 hours 
prior to processing for immunoblot analysis or immunofluorescence microscopy. 
2.5 Adenovirus amplification 
The adenoviruses encoding Cre recombinase and green fluorescent protein (GFP) (Ad-
Cre), β-galactosidase and GFP (Ad-βgal), or human ILK and GFP (Ad-hILK) were 
generated in our laboratory and have been described (Vespa et al. 2003, Vi et al. 2011). 
High-titer adenovirus stocks (10
8
-10
9
 virus/ml) were prepared using the human 
embryonic kidney cell line HEK293 (American Type Culture Collection, Manassas, VA). 
HEK293 cells were cultured in HyQ-DMEM-RS medium supplemented with 4% FBS in 
150-cm
2
 cell culture flasks. When the cells had reached 80% confluence, they were 
gently washed with sterile phosphate-buffered saline (PBS). A solution containing serum-
free HyQ-DMEM-RS and adenoviruses at a multiplicity of infection (MOI) of 1 was 
added to the cells. The cells were incubated for 1 hour at 37°C, to allow infection to 
proceed. After 1 hour, 10 ml of HyQ-DMEM-RS containing 4% FBS was added, to give 
a final concentration of 2% FBS. The infected HEK293 cells were cultured at 37°C in a  
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Figure 2. 1. Schematics of plasmids used in transfections 
The vectors encoding V5-tagged wild-type and mutant ILK have a CMV promoter 
(pCMV), a wild-type or mutant ILK construct with C-terminal V5 tag, and ampicillin 
resistance gene (Amp). The vectors encoding HA-tagged wild-type and mutant TβRII 
have a CMV promoter, a wild-type or mutant TβRII construct with C-terminal HA tag, 
and ampicillin resistance gene (Amp). 
pCMV
ILK
construct
V5
Amp
pcDNA3.1-ILK-V5
pCMV
TβRII
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humidified atmosphere with 5% CO2 until 70% of the cells had lifted from the culture 
flask (7-10 days). The remaining cells were detached from the culture flask by rinsing 
with culture medium. The cell suspension was transferred to a conical tube and 
centrifuged at 1800 x g at 22°C for 5 minutes. The culture medium was removed by 
aspiration, and the cell pellet was resuspended in PBS containing 10% glycerol (300-500 
μl per 150-cm2 culture flask). The cell suspension was subjected to three freeze-thaw 
cycles using liquid nitrogen and a 37°C water bath. Lysed cells were then centrifuged at 
3000 x g at 4°C for 10 minutes and the supernatant containing the adenoviruses was 
collected and stored in 100-μl aliquots at -80°C until ready to use. Adenovirus stocks 
were titered by dilution assay, in which HEK293 cells were infected with various 
dilutions of virus solution for 1 hour and were fixed 24 hours after infection. The cell 
nuclei were stained using Hoechst 33342 and the percentage of GFP-positive cells was 
calculated. With the assumption that one viral particle is required to infect one HEK293 
cell, the number of infectious viral particles per volume of solution was calculated. 
2.6 Adenoviral transduction of primary cells 
2.6.1 Dermal fibroblasts 
Dermal fibroblasts at 90-95% confluence in 10-cm culture dishes were infected with Ad-
Cre, Ad-βgal, or Ad-hILK in 4 ml of serum-free HyQ-DMEM-RS at a MOI of 150. 
Under these conditions, ≥95% of the cells were infected, as confirmed by GFP 
fluorescence, with no significant reduction in cell viability. After 4 hours, 4 ml of HyQ-
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DMEM-RS with 4% FBS was added to the cells to give a final concentration of 2% FBS. 
The cells were cultured for 4 days prior to being used for experiments. 
For experiments involving two infections, the second infection was conducted 2 days 
after the first infection with a MOI of 150, and the cells were collected 4 days after the 
initial infection. 
2.6.2 Epidermal keratinocytes 
Keratinocytes at 80-95% confluence were infected with Ad-Cre or Ad-βgal in serum-free, 
Ca
2+
-free EMEM supplemented with 25 μg/ml BSA at a MOI of 5-20. Under these 
conditions, ≥95% of the cells were infected, as confirmed by GFP fluorescence, with no 
significant reduction in cell viability. Five hours after infection, the medium was replaced 
with keratinocyte growth medium. The cells were cultured for 3 days prior to being used 
for experiments. 
2.7 Preparation of cell lysates and immunoprecipitation 
Cells were collected for preparation of lysates 24-48 hours after transfection, or 72-96 
hours after infection, as described in individual experiments. The cells were scraped from 
the culture dishes and centrifuged (200 x g at 4°C, for 10 minutes). The cell pellets were 
stored at -80°C or processed immediately to prepare lysates. 
In experiments in which analyses of phosphorylated proteins were conducted, cells were 
resuspended in Phospho Safe extraction reagent supplemented with 1 mM PMSF and 
placed on ice for 30 minutes. The volume of extraction reagent used was approximately 
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4-fold larger than the estimated size of the cell pellet. The lysates were centrifuged at 
18,000 x g, at 4°C, for 10 minutes, and the supernatant was transferred to a new tube. 
Bradford protein quantification assays were conducted to determine the protein 
concentration in each lysates sample. To detect endogenous proteins by Western blot 
analyses, 50 μg of protein per sample were used, whereas 20 μg of protein per sample 
were used to detect exogenously expressed proteins. 
For immunoprecipitation experiments, IMDF cells or dermal fibroblasts were lysed in a 
modified radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1 mM PMSF, 10 mM Na3VO4, 1 
μg/ml NaF, 1 μg/ml aprotinin, 1 μg/ml pepstatin, and 1 μg/ml leupeptin) for 30 minutes 
on ice. The volume of lysis buffer used was approximately 4-fold larger than the 
estimated size of the cell pellet. The lysate was centrifuged (18,000 x g, at 4°C for 10 
minutes) and the supernatant was transferred to a new tube. Bradford protein 
quantification assays were conducted to determine the protein concentration in each 
lysates sample. For immunoprecipitation, lysates (500 μg of protein from IMDF cells or 1 
mg of protein from fibroblasts) were incubated with 2 μg of antibodies indicated in 
specific experiments at 4°C with rocking, for 16 hours. Pierce protein A/G magnetic 
beads were added to the lysate-antibody mixtures (25 μl per sample), mixed, and 
incubated for 1 hour at 22°C with gentle rocking. The beads were rinsed 5-8 times with 
PBS containing 0.02% Tween-20, using 300-500 μl per wash. Antibody/antigen 
complexes were eluted and denatured by incubating the beads in 1x loading buffer (50 
mM Tris-Cl pH 6.8, 2% sodium dodecyl sulphate, 0.1% bromophenol blue, 10% 
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glycerol) with 10 mM DTT at 22°C for 10 min. The immunecomplexes were resolved by 
denaturing polyacrylamide gel electrophoresis (SDS-PAGE). 
2.8 Denaturing polyacrylamide gel electrophoresis and 
immunoblotting 
Samples of cell lysates or immunoprecipitates were resolved by electrophoresis on SDS-
PAGE (5% stacking and 8% resolving polyacrylamide gels). Following electrophoresis, 
the proteins were transferred to Immobilon-P PVDF transfer membranes. The membranes 
were blocked with Tris-buffered saline (TBS, 100mM Tris-HCL pH 7.5 and 0.9% NaCl) 
containing 0.05% Tween-20 and 5% skim milk (TBS-TM), for 1 hour at 22°C, with 
gentle rocking. The membranes were probed with primary antibodies indicated in 
individual experiments, diluted in TBS containing 0.05% Tween-20 (TBS-T) or TBS-TM. 
For antibody probing, the membranes were placed in a 50-ml Falcon
TM
 tube containing 5-
7.5 ml of antibody solution, and were fastened to a rotor. The samples were then 
subjected to rotation at 8 rpm at 22°C for 2 hours or at 4°C for 16 hours. The antibody 
dilutions and conditions for probing used were: β-tubulin (1:50 v/v in TBS-T), TβRII, 
ILK, pSMAD2, and HA (1:1000 v/v in TBS-TM), SMAD2/3 (1:1000 v/v in TBS-T), V5 
(1:5000 v/v in TBS-T), GAPDH (1:7500 v/v in TBS-T), and γ-tubulin (1:50000 v/v in 
TBS-T). Following incubation with primary antibody, the membranes were washed with 
15 ml of TBS-T three times, for 10-20 minutes per wash, and then incubated with the 
appropriate HRP-conjugated secondary antibody (1:5000 v/v in TBS-TM) for 1 hour at 
22°C. Proteins on the membranes were detected using Amersham ECL Prime Western 
Blotting Detection Reagent and UltraCruz autoradiography film. All results shown are 
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representative of at least three experiments. When necessary, PVDF membranes were 
stripped before being re-probed to detect other proteins, using a guanidine hydrochloride-
based stripping solution (6M guanidine hydrochiloride, 0.02% NP-40, 20 mM Tris-HCl 
pH 7.5, and 0.8% 2-mercaptoethanol) (Yeung & Stanley 2009). To this end, the 
membranes were incubated with stripping solution for 5 minutes twice, with gentle 
rocking, at 22°C, and then washed with 15 ml of TBS-T three times, 10 minutes per wash, 
before being probed with another primary antibody. 
2.9 Confocal microscopy 
Glass coverslips were submerged in 1M HCl and heated to 50-60°C for 4-16 hours. The 
solution was allowed to cool and the coverslips were washed extensively with 18 MΩ 
water. The coverslips were rinsed in ethanol and allowed to air dry. Once dry, the 
coverslips were coated with 1mg/ml poly-L-lysine (PLL) solution for at least 30 minutes 
at 22°C, with gentle rocking. PLL-treated coverslips were then washed extensively with 
18 MΩ water and allowed to air dry. The PLL-coated coverslips were sterilized by 
incubating in 70% ethanol for 10 minutes at 22°C, and they were washed with 1ml of 
sterile PBS three times. IMDF cells were cultured on sterile PLL-coated glass coverslips. 
For keratinocytes, sterile PLL-coated glass coverslips were further treated with a solution 
containing 50 μg/ml rat tail collagen I dissolved in 0.02N acetic acid for 4 hours at 37°C. 
The coverslips were then washed with 1 ml of sterile PBS three times and then 
keratinocytes were cultured on these coverslips until ready to be processed for 
microscopy. To this end, the cells were fixed with freshly diluted 4% PFA in PBS for 40 
minutes on ice. Cells were then washed for 10 minutes with 1 ml PBS three times, and 
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permeabilized with 0.1% Triton X-100 in PBS for 30 minutes at 22°C. The samples were 
then washed for 10 minutes with 1 ml PBS three times, and incubated in PBS containing 
1% skim milk and 1% goat serum for 1 hour at 22°C. The samples were washed three 
times with 1 ml PBS for 10 minutes each, and probed with primary antibodies indicated 
in individual experiments, with gentle rocking at 22°C for 2 hours or at 4°C for 16 hours. 
The antibodies were diluted in PBS containing 1% skim milk and 5% goat serum The 
antibody dilutions used were: HA (1:500 v/v) and V5 (1:1000 v/v). Following incubation 
with primary antibodies, cells were washed with PBS three times for 10 minutes each, 
with gentle rocking at 22°C. The samples were then incubated with appropriate 
AlexaFluor™-conjugated secondary antibodies (1:1000 v/v in PBS with 1% skim milk 
and 1% goat serum) for 1 hour at 22°C, protected from light. After three 10-minute 
washes with PBS, coverslips were incubated with Hoechst 33342 (1:10000 v/v, 1μg/ml, 
final) for 15 minutes, rocking, at 22°C. The glass coverslips were washed three times 
with 1 ml PBS (10 minutes each) and mounted on microscope slides, using Immu-mount 
mounting medium and allowed to dry overnight at 22°C, protected from light. A Zeiss 
LSM5 DUO scanner laser confocal microscope (Jena, Germany) equipped with a 63x/1.4 
NA oil immersion lens and ZEN 2009 software (Zeiss, Germany) were used to obtain 
images. 
2.10 Cell treatment with TGF-β1, SB431542, and nystatin 
For TGF-β1 treatments, fibroblasts or keratinocytes were incubated, respectively, in 
serum-free HyQ-DMEM-RS or serum-free Ca
2+
-free EMEM containing 25 μg/ml BSA, 
for 4 hours at 37°C. TGF-β1 (10 ng/ml, final) or sterile 18 MΩ water (vehicle) was added 
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into the medium dropwise and gently mixed. The cells were incubated for 1 hour at 37°C 
prior to processing. For experiments using SB431452, fibroblasts were incubated in 
serum-free HyQ-DMEM-RS for 3.5 hours at 37°C. SB431542 (10 μM, final) or sterile 
dimethyl sulfoxide (DMSO, vehicle, 1:1000 v/v, final) was added directly to the medium 
dropwise. Thirty minutes after treatment with SB431542 or DMSO, TGF-β1 (10 ng/ml, 
final) or sterile 18 MΩ water was added to the cell culture medium dropwise and cells 
were cultured at 37°C for 1 hour. For nystatin treatments, cells were incubated in serum-
free HyQ-DMEM-RS supplemented with nystatin (50 μg/ml, final) or sterile DMSO 
(vehicle, 1:100 v/v, final) for 4 hours at 37°C. TGF-β1 (10 ng/ml, final) or sterile 18 MΩ 
water (vehicle) was added to the culture medium for one additional hour. 
2.11 Densitometric analyses and statistics 
ImageJ (Fiji) was used for densitometric analyses (Schindelin et al. 2012). Rectangles of 
equal sizes were drawn around the bands of interest on scanned images of immunoblots. 
A profile plot of each band was obtained, which represents the density in the given 
rectangle. Background values were subtracted, and the densitometric value of each lane 
was obtained. In order to compare different immunoblots, the pSMAD2 values and 
SMAD2/3 values of control cells (Ad-βgal-infected cells treated with TGF-β1) were 
assigned the value of 1 and all other values were adjusted accordingly, resulting in 
relative density values of the bands. The relative density values of pSMAD2 were then 
normalized to SMAD2/3 density to obtain adjusted relative values of the bands.  
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One-way analysis of variance (ANOVA) analyses with Newman-Keuls post-hoc test 
were conducted to determine significance of the results. GraphPad Prism version 5 was 
used for statistical analyses and p values less than 0.05 were considered statistically 
significant. 
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Chapter 3 – Results 
3.1 ILK interacts with TβRII 
Our laboratory had previously shown that ILK-deficient primary mouse dermal 
fibroblasts display abnormal responses to TGF-β1 stimulation (Vi et al. 2011). Thus, I 
sought to understand the mechanisms whereby ILK modulates TGF-β1 signal 
transduction pathways in these cells. As an initial step, I investigated if ILK and TβRII 
associate in primary dermal fibroblasts. To this end, I prepared lysates from cells 
incubated in the presence or absence of TGF-β1, and isolated TβRII immunoprecipitates. 
I then analyzed the latter by immunoblot and found the presence of ILK, irrespective of 
whether or not the cells had been stimulated with TGF-β1 (Figure 3.1).  
To investigate whether ILK and TβRII associate in other cell types, I also examined 
IMDF cells, a spontaneously-immortalized line of dermal fibroblasts previously isolated 
in our laboratory (Apostolova et al. 2002). Wild-type V5-tagged ILK and wild-type HA-
tagged TβRII were exogenously expressed in these cells. I isolated HA 
immunoprecipitates, and observed the presence of V5-tagged ILK (Figure 3.2). 
Reciprocally, I observed that TβRII was present in ILK immunecomplexes, indicating 
that the presence of ILK-TβRII complexes is not limited to primary dermal fibroblasts 
(Figure 3.2). 
Having established the presence of ILK-TβRII complexes in dermal fibroblasts, I next 
examined the subcellular localization of these two proteins by confocal microscopy. I  
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Figure 3. 1. Interaction between ILK and TβRII in primary dermal fibroblasts 
Primary dermal fibroblasts were incubated in serum-free HyQ-DMEM-RS for 4 hours at 
37°C, followed by a 1-hour incubation with TGF-β1 (10 ng/ml) or H2O (vehicle). 
Lysates (1 mg protein/sample) were prepared and subjected to immunoprecipitation with 
antibodies against (A) TβRII or (B) ILK, followed by immunoblotting with the indicated 
antibodies. Lysates of cells incubated in HyQ-DMEM-RS supplemented with 8% FBS 
were subjected to immunoprecipitation with antibodies against (A) unrelated rabbit IgG, 
or (B) unrelated mouse IgG, as control. (C) In parallel, samples of the lysates (50 μg 
protein/sample) were resolved by SDS-PAGE and transferred to membranes, which were 
probed with antibodies against TβRII, phosphorylated SMAD2 (pSMAD2), total 
SMAD2/3, ILK and γ-tubulin, which was used to normalize for protein loading. The 
results shown are representative of experiments repeated 3 times. 
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Figure 3. 2. Interaction between exogenously expressed ILK and TβRII in 
IMDF cells 
IMDF cells were transfected with plasmids encoding V5-tagged ILK and/or HA-tagged 
TβRII. The negative sign (-) indicates transfection with empty vector. Fourty-eight hours 
after transfection, cells were lysed and the lysates were subjected to immunoprecipitation 
with antibodies against (A) V5, or (B) HA (500 μg protein/sample). A sample of the 
lysates was also subjected to immunoprecipitation with antibodies against unrelated 
mouse (A) or rabbit (B) IgG, as control. In parallel, aliquots of the lysates (50 μg 
protein/sample) were resolved by SDS-PAGE and transferred to membranes, which were 
probed with antibodies against HA, V5, and γ-tubulin, which was used to normalize for 
protein loading. The results shown are representative of three experiments. 
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transfected IMDF cells with vectors encoding wild-type V5-tagged ILK and wild-type 
HA-tagged TβRII. Transfected cells were then incubated in the presence or absence of 
TGF-β1 for 1 hour, and were then processed for microscopy. I observed ILK 
immunoreactivity throughout the cytoplasm and at the cell edges, in agreement with 
previous reports in other cell types (Ho et al. 2009) (Figure 3.3). In these cells, I also 
observed TβRII immunoreactivity in intracellular vesicles, and at the cell membrane. 
Significantly, ILK and TβRII appeared to colocalize at the cell periphery and in a fraction 
of intracellular vesicles. This pattern of colocalization was similar in the presence and 
absence of TGF-β1, indicating that it does not require a TGF-β1 stimulus (Figure 3.3). 
3.2 ILK-TβRII colocalization is observed in keratinocytes 
As mentioned in section 1.1.4, TβR complexes are endocytosed via caveolae or via 
clathrin-coated pits. However, incubation at 4°C without TGF-β1 stimulation results in 
inhibition of endocytic trafficking, under these conditions, and TβR complexes are 
predominantly observed at the cell membrane (Figure 3.4 A). At this temperature, all 
trafficking is halted, including constitutive endocytosis of TβRII (Ehrlich et al. 2001). In 
addition, it has been reported that no association between TβR and markers of 
internalization (caveolin-1 for lipid-raft/caveolae-mediated endocytosis, and clathrin for 
clathrin-mediated endocytosis) occurs under these conditions (Mitchell et al. 2004). 
Together, these observations suggest that steady state levels of TβRII complexes are 
mostly observed at the cell surface at 4°C. With TGF-β1 stimulation, cells incubated at 
37°C show an increase in TβRI/TβRII complex formation (Figure 3.4 B) and in 
internalization of TβR complexes into endosomes and caveolae (Figure 3.4 C). Over  
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Figure 3. 3. Co-localization of ILK and TβRII in IMDF cells 
IMDF cells were transfected with plasmids encoding V5-tagged ILK and HA-tagged 
TβRII. Fourty-eight hours after transfection, cells were cultured in serum-free HyQ-
DMEM-RS for 4 hours, followed by treatment with TGF-β1 (10 ng/ml) or H2O (vehicle) 
for 1 hour. The cells were processed for confocal microscopy using antibodies against V5 
and HA to visualize ILK and TβRII, respectively. Boxed areas in micrographs c, g, k, and 
o are shown at higher magnification in micrographs d, h, l, and p, respectively. Arrows
indicate areas of ILK and TβRII colocalization. Scale bar = 10 μm. 
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time, TβR complexes in endosomes are sorted for signalling, recycling, or lysosomal 
degradation, whereas those TβR complexes in caveolae will be targeted for degradation 
in proteasomes or lysosomes (Figure 3.4 D). 
To determine if ILK and TβRII show areas of colocalization in other cell types, I 
analyzed primary mouse epidermal keratinocytes, as a model of epithelial cells. In 
addition, I examined the subcellular localization of TβRII and ILK following ligand 
binding. Primary epidermal keratinocytes were transfected with wild-type V5-tagged ILK 
and wild-type HA-tagged TβRII. Twenty-four hours after transfection, the cells were 
incubated at 4°C for 30 minutes in serum- and TGF-β1-free medium, to impair receptor 
endocytosis and trafficking. After incubation at 4°C, the cells were stimulated with TGF-
β1, and incubated at 37°C for 0, 15, 30, or 60 minutes, and processed for confocal 
microscopy. In keratinocytes cultured in serum-free medium without TGF-β1 stimulation, 
I observed ILK-TβRII colocalization in vesicles within the cytosol, as well as at the cell 
membrane (Figure 3.5 A). This indicates that lack of stimulation by the ligand or 
inhibition of TβRII internalization by low temperature does not interfere with ILK-TβRII 
colocalization. Fifteen minutes after TGF-β1 addition to the culture medium, 
colocalization of ILK and TβRII occurred at the cell membrane, as well as in vesicles 
(Figure 3.5 B). Cells stimulated with TGF-β1 showed an apparent increase in 
colocalization along the cell membrane, in agreement with previous reports that TGF-β1 
stimulation leads to increased recruitment of receptors and formation of TβR complexes 
at the cell membrane (Rechtman et al. 2009). Similarly, after 30 and 60 minutes of TGF-
β1 treatment, colocalization between ILK and TβRII was observed at the cell membrane,  
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Figure 3. 4. Schematic representation of the internalization routes of TβR complexes 
TβR complexes containing TβRII and TβRI form at the cell membrane upon ligand 
binding to TβRII. These complexes can be internalized by two different pathways: 
clathrin-mediated and caveolin-mediated endocytosis. (A) TβRI and TβRII can be found 
at the cell membrane as monomers, homodimers, and heterodimers. (B) The formation of 
heterodimeric complexes greatly increases with the binding of TGF-β1 to TβRII. (C) 
TGF-β1 stimulation increases internalization of the receptor complexes through clathrin-
coated pits to form endosomes, or through lipid-rafts to form caveolae/caveolin-positive 
vesicles. (D) Endosomal TβR complexes are sorted, targeted to signalling endosomes, 
and recycled back to the cell membrane. They can also be targeted for degradation by the 
late endosome/lysosome. Alternatively, TβR complexes in caveolae are targeted for 
degradation by proteasomes and/or lysosomes. 
PP
P P
P
P
P
P
P
P
PP
P
P
P P
P
Recycling
Lysosomal
degradation
Proteasomal
degradation
Endosome
Caveolae
Endosome
Caveolae
P P
TGF-β1
TβRI
Nucleus
A
B
C
D
TβRII
TβR complex
Signalling
63
64 
in what appeared to be pseudopodia (Figure 3.5 C, D). Thus, ILK and TβRII show areas 
of colocalization in epidermal keratinocytes at the cell membrane and in intracellular 
vesicles. In cells cultured without TGF-β1 for 1 hour, ILK- TβRII colocalization was also 
observed at the cell membrane and in vesicles (Figure 3.5 E). A similar pattern of 
colocalization was also observed in cells treated with TGF-β1 and continuously incubated 
at 37°C, without cooling (Figure 3.5 F). Thus, ILK-TβRII colocalization and interaction 
are not appreciably altered in the presence of TGF-β1 (Figures 3.1 and 3.3). 
Another observation to note is that TβRII does not colocalize with ILK at areas that 
appear to be focal adhesions (Figure 3.5 A, B), suggesting the possibility that a separate 
pool of ILK that localizes to focal adhesions to transduce ECM signals, but not 
necessarily TβR signalling, may exist in cells. 
3.3 Mapping of protein regions implicated in the ILK-TβRII 
interaction 
To determine the regions in ILK and in TβRII necessary for the interaction between these 
two proteins, I exogenously expressed various ILK and TβRII mutants in IMDF cells. 
The ILK mutants I tested included ILK E359K and several deletion mutants (amino acids 
67-452, 191-452, 1-300, 1-250, and 1-192) (Figure 3.6 A). ILK E359K is unable to bind 
many proteins that localize to focal adhesions, such as paxillin, α-parvin, and β-parvin, 
and does not localize to focal adhesions (Wu & Dedhar 2001, Nikolopoulos & Turner 
2002). ILK 67-452 is missing its first two ankyrin repeats, and thus is unable to bind to 
PINCH (Tu et al. 1999, Li et al. 1999, Vespa et al. 2005), and it also fails to localize to  
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Figure 3. 5. Colocalization of ILK and TβRII in keratinocytes 
Epidermal keratinocytes were transfected with plasmids encoding V5-tagged ILK and 
HA-tagged TβRII. Fourty-eight hours after transfection, cells were cultured in serum- and 
Ca2+-free EMEM for 4 hours, followed by (A) incubation on ice for 30 minutes, (B-E) 
incubation on ice for 30 minutes, then treatment with TGF-β1 (10 ng/ml) or H2O (vehicle) 
for the indicated times, or (F) treatment with TGF-β1 (10 ng/ml) for 1 hour at 37°C. After 
these treatments, the cells were processed for confocal microscopy, using antibodies 
against V5 and HA to visualize ILK and TβRII, respectively. Boxed areas in micrographs 
c, g, k, o, s, and w are shown at higher magnification in micrographs d, h, i, p, t, and x, 
respectively. Arrows indicate areas of ILK and TβRII colocalization. Scale bar = 10 μm. 
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focal adhesions (Li et al. 1999), cell borders (Vespa et al. 2005), or the nucleus (Nakrieko 
et al. 2008b). The ILK 191-452 mutant lacks all ankyrin repeats. The ILK 1-300 and 1-
250 mutants lack part of the kinase-like domain, including the amino acid residues 
predicted to mediate interactions with β1 integrin (293-451) (Hannigan et al. 1996). 
Lastly, ILK 1-192 lacks the kinase-like domain and cannot interact with focal adhesion-
associated proteins, such as paxillin, α-parvin, and β-parvin, and is unable to localize to 
focal adhesions (Wu & Dedhar 2001), similar to ILK E359K. 
Vectors encoding V5-tagged ILK mutants were transiently transfected in IMDF cells, 
together with wild-type HA-tagged TβRII. Cell lysates from transfected cells were 
prepared for immunoprecipitation. I observed that all of the V5-tagged ILK mutants were 
present in HA immunecomplexes (Figure 3.6 B, C). These results suggest that ILK may 
be able to bind TβRII through multiple sites. These data also indicate that direct binding 
of ILK with paxillin, parvins, PINCH, or β1 integrin is dispensable for its interaction with 
TβRII. Thus, the disruption in the ability of ILK to localize to focal adhesion does not 
affect its capacity to interact with TβRII. 
To complete the mapping of regions important for ILK-TβRII interaction, TβRII 
truncation mutants (Figure 3.7 A) were transiently transfected into IMDF cells, together 
with wild-type V5-tagged ILK. The HA-tagged TβRII mutants used were TβRII K277R, 
which lacks kinase activity, and two truncation mutants: TβRII 155-567, which lacks 
most of the extracellular domain, and TβRII 1-199, which lacks most of the intracellular 
kinase domain. The last two mutants contain the transmembrane domain. 
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Figure 3. 6. Regions of ILK involved in the ILK-TβRII interaction 
 (A) Schematic diagram of the V5-tagged human ILK mutants used. Wild-type ILK 
includes 5 ankyrin repeats, a pleckstrin homology-like domain (PH), and a kinase-like 
domain (KLD). The asterisk indicates mutation of the E residue at position 359 to K. (B) 
IMDF cells were transfected with plasmids encoding V5-tagged ILK mutants and/or HA-
tagged wild-type TβRII. The negative sign (-) indicates transfection with an empty vector. 
Fourty-eight hours after transfection, lysates (500 μg protein/sample) were prepared and 
subjected to immunoprecipitation with antibodies against HA or unrelated rabbit IgG, as 
control, followed by immunoblotting with the indicated antibodies. In parallel, samples of 
the lysates (20 μg protein/sample) were resolved by SDS-PAGE and transferred to PVDF 
membranes, which were probed with antibodies against HA, V5, and γ-tubulin, which 
was used to normalize for protein loading. The results shown are representative of 
experiments repeated 3 times. 
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Immunoprecipitation experiments showed that wild-type ILK interacts with TβRII 
K277R and TβRII 155-567 (Figure 3.7 B), indicating that ILK-TβRII interaction does not 
require either kinase activity of TβRII or its extracellular domain. Notably, ILK and 
TβRII 1-199 also interact (Figure 3.7 B), suggesting that a small cytoplasmic region on 
TβRII 1-199 is sufficient for this interaction to occur, or alternatively, that there is an 
intermediate adaptor protein, possibly with a transmembrane domain, linking ILK and 
TβRII. 
3.4 The kinase activity of TβRI is dispensable for ILK-TβRII 
complex formation 
Given that neither TGF-β1 stimulation nor TβRII kinase activity are required for ILK-
TβRII interactions (Figures 3.1 and 3.7B), I sought to determine the role of TβRI kinase 
activity. Primary dermal fibroblasts were treated with SB-431542, a highly selective 
TβRI kinase inhibitor, or vehicle, and then incubated with TGF-β1 (or control vehicle). I 
isolated ILK by immunoprecipitation from these cells, and analyzed them for the 
presence of TβRII. As previously observed (Figure 3.1), TGF-β1 treatment is not 
required for ILK-TβRII interaction (Figure 3.8). I also observed the presence of TβRII in 
ILK immunoprecipitates, irrespective of whether or not cells had been treated with SB-
431542 (Figure 3.8). Hence, the kinase function of TβRI and the presence of an activated 
TβRI-TβRII species are not necessary for ILK-TβRII interactions to occur. 
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Figure 3. 7. Regions of TβRII involved in the ILK-TβRII interaction 
(A) Schematic of the HA-tagged human TβRII mutants used. Wild-type TβRII contains a 
signal sequence (SS), an extracellular domain (EC), a transmembrane domain (TM), and 
an intracellular kinase domain. The asterisk indicates mutation of the K residue at 
position 277 to R. (B) IMDF cells were transfected with plasmids encoding HA-tagged 
TβRII mutants and V5-tagged wild-type ILK. The negative sign (-) indicates transfection 
with empty vector. Fourty-eight hours after transfection, the cells were lysed, and the 
lysates (500 μg protein/sample) were subjected to immunoprecipitation with antibodies 
against ILK or unrelated mouse IgG, as control, followed by immunoblotting with the 
indicated antibodies. In parallel, samples of the lysates (20 μg protein/sample) were 
resolved by SDS-PAGE and transferred to membranes, which were probed with 
antibodies against HA, V5, and γ-tubulin, which was used to normalize for protein 
loading. The results shown are representative of experiments repeated 3 times. 
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Figure 3. 8. Effect of TβRI kinase inhibition on ILK-TβRII interaction 
Primary dermal fibroblasts were incubated in serum-free HyQ-DMEM-RS for 3.5 hours 
at 37°C, treated with SB431542 or DMSO (vehicle) for 0.5 hours, and then treated with 
TGF-β1 or water (vehicle) for 1 hour. Lysates (1 mg protein/sample) were prepared and 
subjected to immunoprecipitation with antibodies against ILK or unrelated mouse IgG, as 
control, followed by immunoblotting with antibodies against TβRII. In parallel, samples 
of the lysates (50 μg protein/sample) were resolved by SDS-PAGE and transferred to 
membranes, which were probed with antibodies against pSMAD2, SMAD2/3, ILK, and 
γ-tubulin, which was used to normalize for protein loading. The results shown are 
representative of experiments repeated 3 times. 
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3.5 Abrogation of ILK expression results in abnormal 
responses to TGF-β1 
I next studied the effects of inactivating the Ilk gene and, consequently, of disrupting the 
ILK-TβRII interaction, using Ilkf/f dermal fibroblasts. By infecting these cells with 
adenoviruses encoding Cre-recombinase (Ad-Cre), the Ilk gene was inactivated and the 
levels of ILK decreased by ≥ 90% after a period of four days (Figure 3.9 A). Specifically, 
there is a substantial decrease in the level of ILK by 72 hours, and by 94 hours after 
infection, ILK is barely detected. Thus, all experiments using ILK-deficient dermal 
fibroblasts were conducted between 72 and 94 hours after infection. This experimental 
system allowed me to address the role of ILK on TβR signalling.  
In a first set of experiments, primary dermal fibroblasts were infected with Ad-Cre or a 
recombinant adenovirus encoding β-galactosidase (Ad-βgal) as control. Four days after 
infection, the cells were incubated in serum-free medium for 4 hours, and then treated 
with TGF-β1 or vehicle for 1 hour. The levels of phosphorylated SMAD2 (pSMAD2) 
were used as an indicator of TβR signalling. In the absence of ILK, I observed attenuated 
TβR signalling, as evidenced by reduced pSMAD2 levels, relative to those in ILK-
expressing cells (Figure 3.9 B), as previously described by Vi et al. (Vi et al. 2011).  
To confirm that ILK deficiency is directly linked to abnormal TβR signalling, exogenous 
expression of wild-type human ILK (hILK) was induced in ILK-deficient fibroblasts. To 
this end, primary dermal fibroblasts that had already been infected with Ad-Cre or Ad-
βgal were infected again 48 hours later with Ad-hILK or Ad-βgal. Four days after the 
first infection, cells were serum-starved, and then treated with TGF-β1 or vehicle for 1  
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Figure 3. 9. Effects of Ilk gene inactivation on TβR signalling in dermal fibroblasts 
(A) Primary Ilkf/f dermal fibroblasts were infected with adenoviruses encoding Cre 
recombinase (Ad-Cre) at an MOI of 150, and cell lysates were prepared at the indicated 
times after infection. The cell lysates were analyzed by immunoblot, using anti-ILK 
antibodies. β-Tubulin was used to normalize for protein loading. All experiments 
involving Ilk gene inactivation were conducted 94 hours after infecting the cells with Ad-
Cre. (B) Primary dermal fibroblasts were infected with Ad-Cre (ILK-deficient) or Ad-
βgal (ILK-expressing) at an MOI of 150. Ninety-four hours after infection, the cells were 
incubated in serum-free HyQ-DMEM-RS for 4 hours at 37°C, followed by 1-hour 
incubation with TGF-β1 (10 ng/ml) or H2O (vehicle). The cells were lysed, and the 
lysates (50 μg protein/sample) were analyzed by immunoblotting, using antibodies 
against pSMAD2, SMAD2/3, ILK, and GAPDH, which was used to normalize for 
protein loading. The results shown are representative of experiments repeated 3 times. 
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hour. I observed that the level of pSMAD2 increased with TGF-β1 stimulation in ILK-
expressing cells. In contrast, substantially lower levels of pSMAD2 were observed 
following TGF-β1 stimulation in ILK-deficient cells (Figure 3.10 A). Significantly, cells 
deficient in endogenous ILK, but expressing exogenous human ILK showed fully 
restored levels of pSMAD2 in response to TGF-β1 treatment (Figure 3.10 A, B). This 
confirms my findings that ILK is essential for normal TβR signalling in primary dermal 
fibroblasts and that ILK deficiency is directly linked to abnormal TGF-β1 signal 
transduction. Notably, fibroblasts that express both endogenous and exogenous ILK show 
somewhat lower levels of pSMAD2 in response to TGF-β1 stimulation (Figure 3.10 A, 
B). This suggests that optimal ILK levels may be necessary for normal TβR signalling in 
these cells. 
3.6 Ilk gene inactivation results in abnormal TβR signalling 
in keratinocytes 
Given that ILK-TβRII colocalization was observed in keratinocytes (Figure 3.5), I sought 
to determine whether ILK-deficient keratinocytes display abnormal responses to TGF-β1, 
similar to ILK-deficient fibroblasts. To address this question, Ilkf/f keratinocytes were 
infected with Ad-Cre or Ad-βgal. Experiments were conducted 3 days after infection 
because in these cells, ILK levels decrease by ≥ 90 % over a period of three days 
(Nakrieko et al. 2008a), and the viability of ILK-deficient keratinocytes decreases 4 days 
after infection with Ad-Cre. The cells were incubated in serum-free medium, and then 
treated with TGF-β1 or vehicle for 1 hour. Non-infected, ILK-expressing keratinocytes 
show significantly higher levels of pSMAD2 with TGF-β1 stimulation, compared to ILK- 
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Figure 3. 10. Effect of Ilk gene inactivation on responses to TGF-β1 stimulation 
in dermal fibroblasts 
(A) Fourty-eight hours after primary Ilkf/f dermal fibroblasts were infected with Ad-Cre 
(ILK-deficient) or Ad-βgal (ILK-expressing) at an MOI of 150, the cells were infected 
again with recombinant adenoviruses encoding V5-tagged human ILK (Ad-hILK) or Ad-
βgal at an MOI of 150. Ninety-four hours after the first infection, cells were incubated in 
serum-free HyQ-DMEM-RS for 4 hours, and then treated with TGF-β1 (10 ng/ml) or 
H2O (vehicle) for 1 hour. The cells were lysed, and the lysates (50 μg protein/sample) 
were processed for immunoblotting using antibodies against pSMAD2, SMAD2/3, ILK, 
and GAPDH, which was used to normalize for protein loading. The arrow indicates 
exogenously expressed V5-tagged wild-type human ILK, and the arrowhead indicates 
endogenous wild-type mouse ILK. (B) Densitometric measurements were conducted to 
quantify the relative abundance of pSMAD2 levels, which were normalized to the total 
SMAD2/3 levels. The results are expressed as the mean + SEM. The asterisks indicate 
p<0.05 (ANOVA, Newman-Keuls post-hoc test, n = 4). 
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deficient cells (Figure 3.11 A, B). The levels of pSMAD2 in ILK-deficient cells treated 
with TGF-β1 are also significantly lower those in Ad-βgal-infected cells treated with 
TGF-β1 (Figure 3.11 A, B). Thus, ILK-deficient keratinocytes display abnormal TβR 
signalling, similar to ILK-deficient fibroblasts, and ILK appears to play a crucial role in 
modulating TβR signalling in cultured keratinocytes, as well as in fibroblasts. 
3.7 Inhibition of lipid-raft formation results in restoration of 
TβR signalling in ILK-deficient fibroblasts 
Given that ILK-deficient fibroblasts display abnormal TβR signalling, we had previously 
assessed if TβR levels are altered in ILK-deficient fibroblasts, and we observed that 
steady-state levels of TβRII, but not TβRI, are decreased in the absence of ILK 
(Appendix A; L Vi, S Boo & L Dagnino, unpublished data). We further determined that 
the decrease in TβRII levels was associated with increased TβRII ubiquitination, 
suggesting increased proteasomal degradation of TβRII in ILK-deficient dermal 
fibroblasts (Appendix B; L Vi, S Boo & L Dagnino, unpublished data). Thus, we used 
MG132, a proteasomal inhibitor, to determine whether inhibition of TβRII proteasomal 
degradation could restore the abnormal responses to TGF-β1 stimulation in ILK-deficient 
fibroblasts. For these experiments, primary dermal fibroblasts were infected with Ad-βgal 
or Ad-Cre. Four days after infection, cells were treated with MG132 or vehicle, and then 
treated with TGF-β1. We observed that ILK-deficient fibroblasts displayed lower levels 
of pSMAD2 compared to ILK-expressing cells, when treated with TGF-β1 (Appendix C). 
More importantly, MG132-treated ILK-deficient fibroblasts displayed similar levels of 
pSMAD2 to TGF-β1-treated, ILK-expressing fibroblasts (Appendix C). This suggests  
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Figure 3. 11. Effects of Ilk gene inactivation on TβR signalling in epidermal 
keratinocytes 
(A) Primary epidermal keratinocytes were infected with Ad-Cre (ILK-deficient) at MOI 
of 20, or with Ad-βgal (ILK-expressing) at MOI of 5. Seventy-two hours after infection, 
the cells were incubated in serum-and Ca2+-free EMEM for 4 hours at 37°C, and then 
treated with TGF-β1 (10 ng/ml) or H2O (vehicle) for 1 hour. Lysates were prepared (50 
μg protein/sample) and processed for immunoblotting using antibodies against pSMAD2, 
SMAD2/3, ILK, and γ-tubulin, which was used to normalize for protein loading. (B) 
Densitometric measurements were conducted to quantify the relative abundance of 
pSMAD2 levels, which were normalized to the total SMAD2/3 levels. The results are 
expressed as mean + SEM. The asterisks indicate p<0.05 (ANOVA, Newman-Keuls 
post-hoc test, n = 4). 
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that, by inhibiting proteasomal degradation of TβRII, the TGF-β signalling pathway was 
restored in ILK-deficient fibroblasts. To further validate this finding, I examined the 
effects of nystatin on TβR signalling in ILK-deficient fibroblasts. Nystatin is a 
cholesterol sequestering agent that inhibits the formation of lipid-rafts, which are 
important for formation of caveolin-positive vesicles (Figure 1.3). TGF-β receptor 
complexes in caveolin-positive vesicles are ubiquitinated and targeted for proteasomal 
degradation. By inhibiting formation of lipid rafts, subsequent proteasomal degradation 
of receptor complexes is hindered (Di Guglielmo et al. 2003). 
Thus, I generated ILK-expressing and ILK-deficient cells by adenoviral infection with 
Ad-βgal and Ad-Cre, as described above. These cultures were then treated with nystatin 
or vehicle in serum-free medium for 4 hours. TGF-β1 or vehicle was then added to the 
growth medium, and cells were incubated for 1 additional hour. ILK-expressing 
fibroblasts showed increased pSMAD2 levels with TGF-β1 stimulation, and these levels 
were not affected by nystatin treatment (Figure 3.12 A, B). As previously observed, ILK-
deficient fibroblasts displayed lower levels of pSMAD2 when treated with TGF-β1 
(Figure 3.12 A). In contrast, when ILK-deficient cells were treated with nystatin and 
TGF-β1, there was a marked increase in pSMAD2 levels (Figure 3.12 A, B). Thus, 
abnormal TβR signalling in ILK-deficient fibroblasts is also restored with nystatin 
treatment, possibly through inhibition of TβR delivery to caveolin-positive vesicles. The 
effects of nystatin treatment in ILK-deficient fibroblasts were similar to those observed in 
our previous experiment using MG132 (Appendix C). These results show that inhibition 
of TβRII degradation pathways, either by interfering with formation of lipid- 
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Figure 3. 12. Effects of nystatin treatment in ILK-deficient dermal fibroblasts 
(A) Ninety-four hours after primary dermal fibroblasts were infected with Ad-Cre (ILK-
deficient) or Ad-βgal (ILK-expressing) at an MOI of 150, cells were incubated in serum-
free HyQ-DMEM-RS supplemented with nystatin (50 μg/ml) or DMSO (vehicle) for 4 
hours at 37°C, and then treated with TGF-β1 (10 ng/ml) or H2O (vehicle) for 1 hour. The 
cells were lysed, and the lysates were processed for immunoblotting using antibodies 
against pSMAD2, SMAD2/3, ILK, and GAPDH, which was used to normalize for 
protein loading. (B) Densitometric measurements were conducted to quantify the relative 
abundance of pSMAD2, which was normalized to the total SMAD2/3 levels. The results 
are expressed as mean + SEM. The asterisk indicates p<0.05 (ANOVA, Newman-Keuls 
post-hoc test, n = 5). 
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rafts or by preventing proteasomal degradation of TβRII, can restore impaired TβR 
signalling associated with loss of ILK. 
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Chapter 4 – Discussion 
4.1 Summary and general discussion 
Myofibroblast differentiation requires normal TβR signalling as well as 
mechanotransduction from ECM signals (reviewed in Hinz 2010). We have previously 
shown that ILK, a scaffolding protein, plays an important role in TβR signalling and in 
myofibroblast differentiation (Vi et al. 2011), as well as in transduction of integrin 
signalling (Vi et al. 2011, reviewed in Wickström et al. 2010a). I have elucidated a 
possible mechanism of action for ILK in modulating TβR signalling. 
4.1.1 Interaction between ILK and TβRII 
As a scaffold protein, ILK interacts with various proteins associated with the actin 
cytoskeleton and with focal adhesion proteins to transduce ECM signals (Wu & Dedhar 
2001, reviewed in Qin & Wu 2012). I showed that ILK and TβRII associate in primary 
dermal fibroblasts and in IMDF cells, which constitute a novel interaction for these two 
proteins. ILK and TβRII colocalize in some intracellular vesicles, and also at the cell 
membrane. The interaction between ILK and TβRII does not require TGF-β1 stimulation 
or the kinase function of either TβRI or TβRII. 
My mapping experiments show that ILK E359K interacts with TβRII. ILK E359K is a 
mutant with impaired ability to bind several focal adhesion proteins, such as α-parvin, β-
parvin, and paxillin. As a result, this mutant also fails to localize to focal adhesions. The 
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observation that this mutant can be found in association with TβRII demonstrates that the 
interaction of ILK and TβRII does not likely occur with focal adhesion involvement, and 
does not require the presence of paxillin, parvins, or PINCH. Consistent with this 
proposal, I observed ILK, but not TβRII, immunoreactivity in structures that appeared to 
be mature focal adhesions, suggesting that the ILK pools involved in focal adhesion 
assembly and/or function are different from those that associate with TβRII. Additional 
experiments are needed to confirm this proposal. 
A deletion mutant containing only the intracellular domain of TβRII associates with ILK, 
which indicates that the extracellular domain of TβRII is dispensable for this interaction. 
Interestingly, a mutant TβRII protein lacking most of the cytoplasmic domain (TβRII 1-
199) also interacts with ILK. This suggests that there may be an intermediate protein with 
a transmembrane domain that interacts with both ILK and the extracellular domain of 
TβRII, serving as a linker between these two proteins. 
4.1.2 Modulatory role of ILK in TβR signalling 
Previously, our laboratory showed that ILK-deficient dermal fibroblasts exhibit 
attenuated responses to stimulation by TGF-β1 (Vi et al. 2011). We now show that this 
effect is directly linked to loss of ILK expression, since expression of exogenous human 
ILK into ILK-deficient mouse dermal fibroblasts result in restoration of pSMAD2 levels 
in response to TGF-β1. It is interesting to note that human ILK, which only differs by 
two amino acids from mouse ILK, was able to restore TβR signalling in ILK-deficient 
mouse dermal fibroblast. However, cells expressing both endogenous ILK and exogenous 
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human ILK show statistically significantly lower levels of TGF-β1-induced pSMAD2 
levels. This signifies that an optimal level of ILK may be required for normal cell 
signalling, a phenomenon often observed with other scaffolding proteins (Witzel et al. 
2012). 
The disruption of ILK-TβRII complexes by Ilk gene inactivation diminishes TβR 
signalling in the context of generation of pSMAD2. However, the significance of the 
ILK-TβRII interaction needs to be further explored, since this approach does not address 
the possibility that ILK may also modulate TβR signalling by mechanisms independent 
of its ability to form complexes with this receptor. To this end, ILK-TβRII interaction 
must be disrupted without changing the levels of ILK and TβRII, and then any changes in 
TβR signalling must be studied. This may be achieved by identifying and expressing an 
ILK mutant that is unable to interact with TβRII. An alternate approach would be to 
determine the specific site required for the interaction between ILK and TβRII, and then 
designing a small molecule inhibitor to abrogate their interaction.  
My observations that Ilk gene inactivation resulted in reduced pSMAD2 levels and 
decreased myofibroblast differentiation in response to TGF-β1 are consistent with 
previous findings by others (Vi et al. 2011, Blumbach et al. 2010). However, Blumbach 
et al. also showed that exogenous TGF-β1 restored myofibroblast differentiation in 
cultured ILK-deficient fibroblasts generated from a different mouse strain, as 
demonstrated by increased pSMAD2 and α-SMA levels in ILK-deficient fibroblasts 
treated with this cytokine (Blumbach et al. 2010). These seemingly contrasting results 
may be explained by the different methods used to create ILK-deficient fibroblasts. In my 
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study, primary dermal fibroblasts were isolated from 3-day-old Ilkf/f mice. The fibroblasts 
were cultured and an acute loss of ILK was induced by adenoviral infection. However, in 
the study by Blumbach et al., transgenic mice with floxed Ilk gene were crossed with 
mice with tamoxifen-regulated Cre recombinase expressed under the control of the 
collagen I promoter, which regulates transcription specifically in fibroblasts. Cre-
mediated recombination was induced in 12-day-old mice by tamoxifen administration for 
5 days and the primary dermal fibroblasts were isolated after tamoxifen induction. Thus, 
fibroblast-restricted Ilk gene inactivation in vivo may have created a more chronic 
condition, where compensatory mechanisms may be triggered in order to maintain 
homeostasis (Blumbach et al. 2010). To summarize, there are a few differences that may 
explain the different observations between the two studies: the strain of mice, the age of 
mice when sacrificed for fibroblast isolation, and the method of Ilk gene inactivation. 
4.1.2.1 Modulatory role of ILK in TβRII degradation and trafficking 
ILK-deficient dermal fibroblasts display abnormal responses to TGF-β1, likely due, at 
least in part, to decreased steady-state levels of TβRII and increased ubiquitination and 
degradation of TβRII (Appendix A, B; L Vi, S Boo & L Dagnino, unpublished data). 
This decrease in TβRII level was abrogated by proteasomal inhibition, which also 
restored pSMAD2 levels in ILK-deficient fibroblasts stimulated with TGF-β1 (Appendix 
C; L Vi, S Boo & L Dagnino, unpublished data). I also observed that disruption of lipid-
raft formation with nystatin, which is necessary to direct TβRII towards the degradation 
pathway, also resulted in restoration of pSMAD2 levels in TGF-β1-treated ILK-deficient 
fibroblasts. Thus, loss of Ilk expression results in increased ubiquitination and 
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degradation of TβRII. This suggests the possibility that ILK may play a role in 
modulation of TβRII trafficking. Only a few proteins have been identified to interact with 
TβRs and regulate TGF-β signalling. For example, as described in chapter 1, SARA 
interacts with SMAD2 and TβR complexes to promote SMAD2 phosphorylation and 
TβR signalling (Tsukazaki et al. 1998), and the interaction between SMAD7 and TβRI 
leads to inhibition of TβR signalling via abrogation of SMAD2/SMAD4 complex 
formation (Hayashi et al. 1997). More recently, disintegrin and metalloproteinase 12 
(ADAM12) has been identified as a binding partner for TβRII, and this interaction 
promotes clathrin-dependent TβR signalling and inhibits TβRII degradation (Atfi et al. 
2007). Discs large homolog 5 (DLG5) has been also shown to interact with TβRI and 
TβRII, promoting proteasomal degradation of TβRI (Sezaki et al. 2013). The 
identification of an interaction between ILK and TβRII and the role ILK plays in 
promoting TβR signalling is novel and an important step to elucidate the mechanisms 
involved in TβR signalling and, possibly, trafficking. 
The notion that ILK participates in plasma membrane organization and trafficking has 
been presented previously. In ILK-expressing mice, caveolin-1 is observed in basal 
keratinocytes, along the basal aspect of the plasma membrane (Wickström et al. 2010b). 
However, ILK-deficient mice showed caveolin-1 expression in basal and suprabasal 
keratinocytes and caveolin-1 showed cytoplasmic distribution, rather than exclusive 
association with the basal aspect of the plasma membrane (Wickström et al. 2010b). The 
abnormal caveolin-1 distribution in ILK-deficient keratinocytes is caused by microtubule 
instability, suggesting that ILK promotes microtubule stability and modulates 
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internalization by caveolae (Wickström et al. 2010b). Furthermore, ILK-deficient 
endothelial cells showed impaired caveolin-1 dynamics and abnormal distribution of 
caveolin-1 within the cell due to disturbed organization of microtubules and actin 
filaments, demonstrating the modulatory role of ILK in the process of endocytosis and 
trafficking (Malan et al. 2013). These studies show that ILK promotes caveolae-mediated 
endocytosis in keratinocytes and endothelial cells. This is different from the model I have 
proposed based on my observations, that ILK either promotes clathrin-mediated 
endocytosis of TβR and/or negatively regulates caveolae-mediated endocytosis in dermal 
fibroblasts (Figure 4.1). Given that different systems were used to conduct these 
experiments, it is plausible that ILK may play a different role in dermal fibroblasts, 
compared to keratinocytes or endothelial cells, and that ILK promotes clathrin-mediated 
TβR signalling and myofibroblast differentiation by negatively regulating TβR 
internalization via caveolae. 
4.2 Significance 
TGF-β1 signalling pathway is one of the fundamental signalling pathways involved in 
many biological and pathological processes, including wound healing and cancer 
progression. TβR signalling leads to different outcomes, depending on the cell type. For 
example, TGF-β1 causes attenuation of cell proliferation in epidermal keratinocytes, but 
proliferation and differentiation of dermal fibroblasts (Matsumoto et al. 1990, Pietenpol 
et al. 1990, reviewed in Hinz 2007). This pathway has been implicated in pathogenesis of 
various disorders, such as fibrosis, impaired wound healing, and cancer, and thus, better  
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Figure 4. 1. Model of TβR signalling modulation by ILK 
ILK-deficient dermal fibroblasts show increased degradation of TβR, suggesting that ILK 
may play a role in modulation of TβRII trafficking. ILK may promote clathrin-mediated 
endocytosis of TβRII and TβR signalling and negatively regulate caveolae-mediated 
endocytosis of TβRII and degradation of TβRs. 
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understanding of the signalling events associated with TβR stimulation would be 
beneficial for developing therapies to treat a variety of disorders. 
There exist many levels of cross modulation of different pathways involved in fibrosis, 
wound healing, and oncogenesis. Based on findings from our laboratory and others, ILK 
seems to be a common downstream effector of the TβR signalling pathway and integrin-
mediated pathways, and thus ILK could potentially be an effective therapeutic target for 
incomplete wound healing, excessive scar formation, and/or cancer. 
The previously unappreciated role of ILK in modulating TβR signalling I have 
demonstrated in dermal fibroblasts and epidermal keratinocytes opens doors to potential 
therapies targeting ILK to modulate TβR signalling in skin diseases with aberrant TβR 
signalling.  
My findings can have potential implications in the treatment of fibrosis, excess scar tissue 
formation, and cancer biology. High levels of ILK expression and TβR signalling have 
been implicated in the progression of various fibrotic disorders (reviewed in McDonald et 
al. 2008). Unfortunately, current treatments for excessive skin scarring are not fully 
effective or in early phases of clinical trials (reviewed in Tziotzios et al. 2012). Recent 
potential therapies that show promising preliminary results involve attenuation of TβR 
signalling by inhibiting TGF-β1 and/or TGF-β2, or by treatment with avotermin (human 
recombinant TGF-β3), which has been shown to reduce scar tissue formation (reviewed 
in Tziotzios et al. 2012, So et al. 2011). TGF-β also plays various roles in cancer 
progression (reviewed in Massagué 2008). Some clinical studies for treating cancer 
involve targeting the TGF-β pathway, and include approaches for inhibition of TGF-β 
97 
production, and the use of anti-TGF-β antibodies and small-molecule inhibitors of TβRs 
(reviewed in Massagué 2008). Thus, ILK, which also modulates TβR signalling, may be 
a therapeutic target for treating abnormal wound healing disorders or cancers associated 
with aberrant responses to TGF-β. 
4.3 Future directions 
My work and the work of others (Vi et al. 2011, Blumbach et al. 2010) show that ILK 
deficiency results in abrogation of TβR signalling. However, it has yet to be determined if 
TβR trafficking is regulated by ILK. Thus, a comparison of TβR distribution and 
internalization in ILK-expressing and ILK-deficient fibroblasts using endocytic markers, 
such as EEA-1, for early endosome, and Cav-1, for caveolae, would help elucidate the 
role ILK may play on TβR trafficking. I also showed that ILK-TβRII colocalization 
occurs in intracellular vesicles. However, the exact nature of these vesicles remains to be 
determined. Thus, trafficking experiments using biotinylated TGF-β1 and markers of 
signalling and degradatory pathway could be conducted to reveal the internalization 
pathway of ILK-TβRII complexes as a function of time. The process of endocytosis, 
sorting of receptor complexes, and recycling or degradation can occur in as little as 10 
minutes (Maxfield & McGraw 2004). Thus, it would be interesting to see the distribution 
of ILK and TβRII in cells treated with TGF-β1 for a shorter period of time than I used in 
my experiments. The use of markers for early endosomes, late endosomes, recycling 
endosomes, and caveolae would also be useful in determining where ILK-TβRII 
complexes reside at different times after TGF-β1 stimulation. 
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In my experiments showing colocalization between ILK and TβRII, I noted ILK, but not 
TβRII, in what appeared to be mature focal adhesions.  Using antibodies against vinculin 
or paxillin, focal adhesions can be identified, and this would help in determining whether 
ILK proteins participating in focal adhesion-mediated signalling are distinct from ILK 
proteins modulating TβR pathway.  
Finally, the interaction between ILK and TβRII on TβR signalling needs to be further 
analysed. Using bacterially-produced ILK and TβRII, it can be determined whether the 
interaction between these proteins is direct or indirect. Finding a mutant ILK that is 
unable to interact with TβRII would be important in determining the significance of this 
interaction on TβR signalling. By introducing this mutant in ILK-deficient fibroblasts, it 
can be determined whether ILK-TβRII interaction is crucial in promoting TβR signalling, 
or if expression of ILK is sufficient for mediating TβR signalling. Alternatively, a mutant 
TβRII that is unable to interact with ILK can be expressed in TβRII-deficient fibroblasts, 
and then the TβR signalling can be studied. A small molecular inhibitor, which impedes 
ILK-TβRII interaction, may also be used. 
99 
 
 
References 
Apostolova MD, Ivanova IA, Dagnino C, D’Souza SJ & Dagnino L (2002). Active 
nuclear import and export pathways regulate E2F-5 subcellular localization. J Biol Chem 
277, 344471-344479. 
Asano Y, Ihn H, Yamane K, Jinnin M & Tamaki K (2006a). Increased expression of 
integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am 
J Pathol 168, 499-510. 
Asano Y, Ihn H, Jinnin M, Mimura Y & Tamaki K (2006b). Involvement of alphavbeta5 
integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts 
derived from localized scleroderma. J Invest Dermatol 126, 1761-1769. 
Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, 
Greenwell-Wild T, Wahl SM, Deng C & Roberts AB (1999). Mice lacking Smad3 show 
accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1, 
260-266. 
Atfi A, Dumont E, Colland F, Bonnier D, L’helgoualc’h A, Prunier C, Ferrand N, 
Clement B, Wewer UM & Theret N (2007). The disintegrin and metalloproteinase 
ADAM12 contributes to TGF-beta signaling through interaction with the type II receptor. 
J Cell Biol 178, 201-208. 
Bierie B & Moses HL (2006). Tumour microenvironment: TGFbeta: the molecular Jekyll 
and Hyde of cancer. Nat Rev Cancer 6, 506-520. 
Blumbach K, Zweers MC, Brunner G, Peters AS, Schmitz M, Schulz JN, Schild A, 
Denton CP, Sakai T, Fässler R, Krieg T & Eckes B (2010). Defective granulation tissue 
formation in mice with specific ablation of integrin-linked kinase in fibroblasts – role of 
TGFβ1 levels and RhoA activity. J Cell Sci 123, 3872-3883. 
Boudeau J, Miranda-Saavedra D, Barton GJ & Alessi DR (2006). Emerging roles of 
pseudokinases. Trends Cell Biol 16, 443-452. 
Brakebusch C, Grose R, Quondamatteo F, Ramirez A, Jorcano JL, Pirro A, Svensson M, 
Herken R, Sakai T, Timpl R, Werner S & Fässler R (2000). Skin and hair follicle 
integrity is crucially dependent on β1 integrin expression on keratinocytes. EMBO J 19, 
3990-4003. 
Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura 
SL, Aldape K, Landers DV, Carpenter W, Gillett N, Sheppard D, Matthay MA, Albelda 
SM, Kramer RH & Pytela R (1995). Expression of the β6 integrin subunit in 
development, neoplasia and tissue repair suggests a role in epithelial remodelling. J Cell 
Sci 108, 2241-2251. 
100 
 
 
Carracedo S, Lu N, Popova SN, Jonsson R, Eckes B & Gullberg D (2010). The fibroblast 
integrin alpha11beta1 is induced in a mechanosensitive manner involving activin A and 
regulates myofibroblast differentiation. J Biol Chem 285, 10434-10445. 
Chin GS, Liu W, Peled Z, Lee TY, Steinbrech DS, Hsu M & Longaker MT (2000). 
Differential expression of transforming growth factor-β receptors I and II and activation 
of Smad 3 in keloid fibroblasts. Plast Reconstr Surg 108, 423-429. 
Chiswell BP, Zhang R, Murphy JW, Boggon TJ & Calderwood DA (2008). The 
structural basis of integrin-linked kinase-PINCH interactions. Proc Natl Acad Sci U S A 
105, 20677-20682. 
Choma DP, Milano V, Pumiglia KM & DiPersio CM (2007). Integrin α3β1-dependent 
activation of FAK/Src regulates Rac1-mediated keratinocyte polarization on laminin-5. J 
Invest Dermatol 127, 31-40. 
Chu H, Thievessen I, Sixt M, Lammermann T, Waisman A, Braun A, Noegel AA & 
Fässler R (2006). Gamma-Parvin is dispensable for hematopoiesis, leukocyte trafficking, 
and T-cell-dependent antibody response. Mol Cell Biol 26, 1817-1825. 
Dagnino L, Ho E & Chang WY (2010). Expression and analysis of exogenous proteins in 
epidermal cells. Methods Mol Biol 585, 93-105. 
Deng JT, Sutherland C, Brautigan DL, Eto M & Walsh MP (2002). Phosphorylation of 
the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase. Biochem 
J 367, 517-524. 
Desmoulière A, Geinoz A, Gabbiani F & Gabbiani G (1993). Transforming growth 
factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue 
myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122, 103-
111. 
Desmoulière A, Chaponnier C & Gabbiani G (2005). Tissue repair, contraction, and the 
myofibroblasts. Wound Repair Regen 13, 7-12. 
Dünker N & Krieglstein K (2000). Targeted mutations of transforming growth factor-β 
genes reveal important roles in mouse development and adult homeostasis. Eur J 
Biochem 267, 6982-6988. 
Edlund S, Bu S, Schuster N, Aspenstrom P, Heuchel R, Heldin NE, ten Dijke P, Helding 
CH & Landstrom M (2003). Transforming growth factor-beta1 (TGF-beta)-induced 
apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-
beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell 14, 
529-544. 
101 
 
 
Ehrlich M, Shmuely A & Henis YI (2001). A single internalization signal from the di-
leucine family is critical for constitutive endocytosis of the type II TGF-beta receptor. J 
Cell Sci 114, 1777-1786. 
Eswaran J, Patnaik D, Filippakopoulos P, Wang F, Stein RL, Murray JW, Higgins JM & 
Knapp S (2009). Structure and functional characterization of the atypical human kinase 
haspin. Proc Natl Acad Sci U S A 106, 20198-20203. 
Flanders KC, Sullivan CD, Fujii M, Sowers A, Anzano MA, Arabshahi A, Major C, 
Deng C, Russo A, Mitchell JB & Roberts AB (2002). Mice lacking Smad3 are protected 
against cutaneous injury induced by ionizing radiation. Am J Pathol 160, 1057-1068. 
Flanders KC (2004). Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 85, 
47-64. 
Fukuda K, Gupta S, Chen K, Wu C & Qin J (2009). The pseudokinase site of ILK is 
essential for its binding to alpha-Parvin and localization to focal adhesions. Mol Cell 36, 
819-830. 
Fukuda K, Knight JD, Piszczek G, Kothary R & Qin J (2011). Biochemical, proteomic, 
structural, and thermodynamic characterizations of integrin-linked kinase (ILK): cross-
validation of the pseudokinase. J Biol Chem 286, 21886-21895. 
Gailit J, Welch MP & Clark RA (1994). TGF-beta 1 stimulates expression of 
keratinocyte integrins during re-epithelialization of cutaneous wounds. J Invest Dermatol 
103, 221-227. 
Geiger B, Spatz JP & Bershadsky AD (2009). Environmental sensing through focal 
adhesions. Nat Rev Mol Cell Biol 10, 21-33. 
Gilboa L, Wells RG, Lodish HF & Henis YI (1998). Oligomeric structure of type I and 
type II transforming growth factor beta receptors: homodimers form in the ER and persist 
at the plasma membrane. J Cell Biol 140, 767-777. 
Grashoff C, Aszodi A, Sakai T, Hunziker EB & Fässler R (2003). Integrin-linked kinase 
regulates chondrocyte shape and proliferation. EMBO Rep 4, 432-438. 
Grose R, Hutter C, Bloch W, Thorey I, Watt FM, Fässler R, Brakebusch C & Werner S 
(2002). A crucial role of beta 1 integrins for keratinocyte migration in vitro and during 
cutaneous wound repair. Development 129, 2303-2315. 
Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, 
Bell jC & Dedhar S (1996). Regulation of cell adhesion and anchorage-dependent growth 
by a new beta 1-integrin-linked protein kinase. Nature 379, 91-96. 
 
102 
 
 
Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnel BW, Richardson MA, Topper JN, 
Gimbrone MA Jr., Wrana JL & Falb D (1997). The MAD-related protein Smad7 
associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. 
Cell 89, 1165-1173. 
He W, Cao T, Smith DA, Myers TE & Wang XJ (2001). Smads mediate signaling of the 
TGFbeta superfamily in normal keratinocytes but are lost during skin chemical 
carcinogenesis. Oncogene 20, 471-483. 
He W, Li AG, Wang D, Han S, Zheng B, Goumans MJ, ten Dijke P & Wang XJ (2002). 
Overexpression of Smad7 results in severe pathological alterations in multiple epithelial 
tissues. EMBO J 21, 2580-2590. 
Henis YI, Moustakas A, Lin HY & Lodish HF (1994). The types II and III transforming 
growth factor-beta receptors form homo-oligomers. J Cell Biol 126,, 139-154. 
Hinz B (2007). Formation and function of the myofibroblast during tissue repair. J Invest 
Dermatol 127, 526-537. 
Hinz B (2010). The myofibroblast: paradigm for a mechanically active cell. J Biomech 
43, 146-155. 
Ho E, Irvine T, Vilk GJ, Lajoie G, Ravichandran KS, D’Souza SJ & Dagnino L (2009). 
Integrin-linked kinase interactions with ELMO2 modulate cell polarity. Mol Biol Cell 20, 
3033-3043. 
Ho E & Dagnino L (2012). Epidermal growth factor induction of front-rear polarity and 
migration in keratinocytes is mediated by integrin-linked kinase and ELMO2. Mol Biol 
Cell 23, 492-502. 
Ito Y, Sarkar P, Mi Q, Wu N, Bringas P Jr, Liu Y, Reddy S, Maxson R, Deng C & Chai 
Y (2001). Overexpression of Smad2 reveals its concerted action with Smad4 in 
regulating TGF-beta-mediated epidermal homeostasis. Dev Biol 236, 181-194. 
Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH & Wrana JL 
(2000). Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta 
receptor for degradation. Mol Cell 6, 1365-1376. 
Lange A, Wickström SA, Jakobson M, Zent R, Sainio K & Fässler R (2009). Integrin-
linked kinase is an adaptor with essential functions during mouse development. Nature 
461, 1002-1006. 
Le Roy C & Wrana JL (2005). Clathrin- and non-clathrin-mediated endocytic regulation 
of cell signalling. Nat Rev Mol Cell Biol 6, 112-126. 
 
103 
 
 
Levy L & Hill CS (2005). Smad4 dependency defines two classes of transforming growth 
factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced 
epithelial-mesenchymal transition from its antiproliferative and migratory responses.  
Mol Cell Biol, 25, 8108-8125. 
Li F, Zhang Y & Wu C (1999). Integrin-linked kinase is localized to cell-matrix focal 
adhesions but not cell-cell adhesion sites and the focal adhesion localization of integrin-
linked kinase is regulated by the PINCH-binding ANK repeats. J Cell Sci 112, 4589-
4599. 
Liu S, Kapoor M, Denton CP, Abraham DJ & Leask A (2009). Loss of beta1 integrin in 
mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis 
Rheum 60, 2817-2821. 
Liu S, Xu SW, Blumbach K, Eastwood M, Denton CP, Eckes B, Krieg T, Abraham DJ & 
Leask A (2010). Expression of integrin beta1 by fibroblasts is required for tissue repair in 
vivo. J Cell Sci 123, 3674-3682. 
Liu S & Leask A (2013). Integrin β1 is required for dermal homeostasis. J Invest 
Dermatol 133, 899-906. 
Liu X, Wen FQ, Kobayashi T, Abe S, Fang Q, Piek E, Bottinger EP, Roberts AB & 
Rennard SI (2003). Smad3 mediates the TGF-beta-induced contraction of type I collagen 
gels by mouse embryo fibroblasts. Cell Motil Cytoskeleton 54, 248, 253. 
Lopez-Casillas F, Wrana JL & Massagué J (1993). Betaglycan presents ligand to the TGF 
beta signaling recepteor. Cell 73, 1435-1444. 
Lorenz K, Grashoff C, Torka R, Sakai T, Langbein L, Bloch W, Aumailley M & Fässler 
R (2007). Integrin-linked kinase is required for epidermal and hair follicle 
morphogenesis. J Cell Biol 177, 501-513. 
Mackinnon AC, Qadota H, Norman KR, Moerman DG & Williams BD (2002). C. 
elegans PAT-4/ILK functions as an adaptor protein withint integrin adhesion complexes. 
Curr Biol 12, 787-797. 
Malan D, Elischer A, Hesse M, Wickström SA, Fleischmann BK & Bloch W (2013). 
Deletion of integrin linked kinase in endothelial cells results in defective RTK signaling 
caused by caveolin1 mislocalization. Development 140, 987-995. 
Margadant C & Sonnenberg A (2010). Integrin-TGF-beta crosstalk in fibrosis, cancer and 
wound healing. EMBO Rep 11, 97-105. 
Margadant C, Charafeddine RA & Sonnenberg A (2010). Unique and redundant 
functions of integrins in the epidermis. FASEB J 24, 4133-4152. 
104 
 
 
Martin P (1997). Wound healing—aiming for perfect skin regeneration. Science 276, 75-
81. 
Martinez-Ferrer M, Afshar-Sherif AR, Uwamariya C, de Crombrugghe B, Davidson JM 
& Bhowmick NA (2010). Dermal transforming growth factor-beta responsiveness 
mediates wound contraction and epithelial closure. Am J Pathol 176, 98-107. 
Massagué J (2008). TGFbeta in cancer. Cell 134, 215-230. 
Matsumoto K, Hashimoto K, Hashiro M, Yoshimasa H & Yoshikawa K (1990). 
Modulation of growth and differentiation in normal human keratinocytes by transforming 
growth factor-beta. J Cell Physiol 145, 95-101. 
Maxfield FR & McGraw TE (2004). Endocytic recycling. Nat Rev Mol Cell Biol 5, 121-
132. 
Maydan M, McDonald PC, Sanghera J, Yan J, Rallis C, Pinchin S, Hannigan GE, Foster 
LJ, Ish-Horowicz D, Walsh MP & Dedhar S (2010). Integrin-linked kinase is functional 
Mn2+-dependent protein kinase that regulates glycogen synthase kinase-3β (GSK-3beta) 
phosphorylation. PLoS One 5, e12356. 
McDonald PC, Fielding AB & Dedhar S (2008). Integrin-linked kinase—essential roles 
in physiology and cancer biology. J Cell Sci 121, 3121-3132. 
Mitchell H, Choudhury A, Pagano RE & Leof EB (2004). Ligand-dependent and –
independent transforming growth factor-beta receptor recycling regulated by clathrin-
mediated endocytosis and Rab11. Mol Biol Cell 15, 4166-4178. 
Miyazono K, Olofsson A, Colosetti P & Heldin CH (1991). A role of the latent TGF-
beta-1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J 10, 1091-
1101. 
Miyazono K, ten Dijke P & Heldin CH (2000). TGF-beta signaling by Smad proteins. 
Adv Immunol 75, 115-157.  
Mu D, Cambier S, Fjellbirkeland L, Baron JL, Münger JS, Kawakatsu H, Sheppard D, 
Broaddus VC & Nishimura SL (2002). The integrin alpha(v)beta8 mediates epithelial 
homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol 157, 
493-507. 
Mucsi I, Skorecki KL & Goldberg HJ (1996). Extracellular signal-regulated kinase and 
the small GTP-binding protein, Rac, contribute to the effects of transforming growth 
factor-beta1 on gene expression. J Biol Chem 271, 16567-16572.  
Mukherjee K, Sharma M, Urlaub H, Bourenkov GP, Jahn R, Sudhof TC & Wahl MC 
(2008). CASK functions as a MG2+-independent neurexin kinase. Cell 133, 328-339. 
105 
 
 
Münger JS, Harpel JG, Giancotti FG & Rifkin DB (1998). Interactions between growth 
factors and integrins: latent forms of transforming growth factor-beta are ligands for the 
integrin alphavbeta1. Mol Biol Cell 9, 2627-2638. 
Münger JS, Huang X, Kawakatsu H, Griffiths MJD, Dalton SL, Wu J, Pittet JF, 
Kaminski N, Garat C, Matthay MA, Rifkin DB & Sheppard D (1999). The integrin alpha 
v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary 
inflammation and fibrosis. Cell 96, 319-328. 
Nakrieko KA, Welch I, Dupuis H, Bryce D, Pajak A, St Arnaud R, Dedhar S, D’Souza SJ 
& Dagnino L (2008a). Impaired hair follicle morphogenesis and polarized keratinocyte 
movement upon conditional inactivation of integrin-linked kinase in the epidermis. Mol 
Biol Cell 19, 1462-1473. 
Nakrieko KA, Vespa A, Mason D, Irvine TS, D’Souza SJ & Dagnino L (2008b). 
Modulation of integrin-linked kinase nucleo-cytoplasmic shuttling by ILKAP and CRM1. 
Cell Cycle 7, 2157-2166. 
Nakrieko KA, Rudkouskaya A, Irvine TS, D’Souza SJ & Dagnino L (2011). Targeted 
inactivation of integrin-linked kinase in hair follicle stem cells reveals an important 
modulatory role in skin repair after injury. Mol Biol Cell 22, 2532-2540. 
Nikolopoulos SN & Turner CE (2002). Molecular dissection of actopaxin-integrin-linked 
kinase-Paxillin interactions and their role in subcellular localization. J Biol Chem 277, 
1568-1575. 
Owens DM, Romero MR, Gardner C & Watt FM (2003). Suprabasal alpha6beta4 
integrin expression in epidermis results in enhanced tumourigenesis and disruption of 
TGFbeta signalling. J Cell Sci 116, 3783-3791. 
Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP 
& Dedhar S (2001). Regulation of protein kinase B/Akt-serine 473 phosphorylation by 
integrin-linked kinase: critical roles for kinase activity and aino acids arginine 211 and 
serine 343.  J Biol Chem 276, 27462-27469. 
Pietenpol JA, Hold JT, Stein RW & Moses HL (1990). Transforming growth factor beta 
1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. 
Proc Natl Acad Sci U S A 87, 3758-3762. 
Pircher E, Jullien P & Lawrence DA (1986). Beta-transforming growth factor is stored in 
human blood platelets as a latent high molecular weight complex. Biochem Biophys Res 
Commun 136, 30-37. 
Prud’homme GJ & Piccirillo CA (2000). The inhibitory effects of transforming growth 
factor-beta-1 (TGF-beta1) in autoimmune diseases. J Autoimmun 14, 23-42. 
106 
 
 
Qiao W, Li AG, Owens P, Xu X, Wang XJ & Deng CX (2006). Hair forllicle defects and 
squamous cell carcinoma formation in Smad4 conditional knockout mouse skin. 
Oncogene 25, 207-217. 
Qin J & Wu C (2012). ILK: a pseudokinase in the center stage of cell-matrix adhesion 
and signaling. Curr Opin Cell Biol 24, 607-613. 
Raghavan S, Bauer C, Mundschau G, Li Q & Fuchs E (2000). Conditional ablation of 
beta1 integrin in skin. Severe defects in epidermal proliferation, basement membrane 
formation, and hair follicle invagiation. J Cell Biol 150, 1149-1160. 
Rechtman MM, Nakaryakov A, Shapira KE, Ehrlich M & Henis YI (2009). Different 
domains regulate homomeric and heteromeric complex formation among type I and type 
II transforming growth factor-beta receptors. J Biol Chem 284, 7843-7852. 
Reynolds LE, Conti FJ, Lucas M, Grose R, Robinson S, Stone M, Saunders G, Dickson C, 
Hynes RO, Lacy-Hulbert A & Hodivala-Dilke K (2005). Accelerated re-epithelialization 
in beta3-integrin-deficient-mice is associated with enhanced TGF-beta1 signaling. Nat 
Med 11, 167-174. 
Reynolds LE, Conti FJ, Silva R, Robinson SD, Iyer V, Rudling R, Cross B, Nye E, Hart 
IR, Dipersio CM & Hodivala-Dilke KM (2008). Alpha3beta1 integrin-controlled Smad7 
regulates reepithelialization during wound healing in mice. J Clin Invest 118, 965-974. 
Runyan CE, Schnaper HW & Poncelet AC (2005). The role of internalization in 
transforming growth factor beta1-induced Smad2 association with Smad anchor for 
receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells. J 
Biol Chem 280, 8300-8308. 
Sakai T, Li S, Docheva D, Grashoff C, Sakai K, Kostka G, Braun A, Pfeifer A, 
Yurchenco PD & Fässler R (2003) Integrin-linked kinase (ILK) is required for polarizing 
the epiblast, cell adhesion, and controlling actin accumulation. Genes Dev 17, 926-940. 
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, 
Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, 
Tomancak P & Cardona A (2012). Fiji: an open-source platform for biological-image 
analysis. Nat Methods 9, 676-682. 
Sezaki T, Tomiyama L, Kimura Y, Ueda K & Kioka N (2013). Dlg5 interacts with the 
TGF-β receptor and promotes its degradation. FEBS Lett 587, 1624-1629. 
Shi Y & Massagué J (2003). Mechanisms of TGF-beta signalling from cell membrane to 
the nucleus. Cell 113, 685-700. 
Silver FH, Siperko LM & Seehra GP (2003). Mechanobiology of force transduction in 
dermal tissue. Skin Res Technol 9, 3-23. 
107 
 
 
Simmons K & Toomre D (2000). Lipid rafts and signal transduction. Nat Rev Mol Cell 
Biol 1, 31-39. 
Singer AJ & Clark RA (1999). Cutaneous wound healing. N Engl J Med 341, 738-746. 
Sirard C, de la Pompa JL, Elia A, Itie A, Mirtosos C, Cheung A, Hahn S, Wakeham A, 
Schwartz L, Kern SE, Rossant J & Mak TW (1998). The tumor suppressor gene 
Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse 
embryo. Genes Dev 12, 107-119. 
So K, McGrouther DA, Bush JA, Durani P, Taylor L, Skotny G, Mason T, Metcalfe A, 
O’kane S & Ferguson MW (2011). Avotermin for scar improvement following scar 
revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II 
clinical trial. Plast Reconstr Surg 128, 163-172. 
Sumiyoshi K, Nakao A, Setoguchi Y, Okumura K, Tsuboi R & Ogawa H (2003). Smads 
regulate collagen gel contraction by human dermal fibroblasts. Br J Dermatol 149, 464-
470. 
Terpstra L, Prud’homme J, Arabian A, Takeda S, Karsenty G, Dedhar S & St Arnaud R 
(2003). Reduced chondrocyte proliferation and chondrodysplasia in mice lacking the 
integrin-linked kinase in chondrocytes. J Cell Biol 162, 139-148. 
Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C & Brown RA (2002). Myofibroblasts 
and mechano-regulation of connective tissue remodeling. Nat Rev Mol Cell Biol 3, 349-
363. 
Tredget EE (1999). Pathophysiology and treatment of fibroproliferative disorders 
following thermal injury. Ann N Y Acad Sci 888, 165-182. 
Tsukazaki T, Chiang TA, Davison AF, Attisano L & Wrana JL (1998). SARA, a FYVE 
domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95, 779-791. 
Tu Y, Li F, Goicoechea S & Wu C (1999). The LIM-only protein PINCH directly 
interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading 
cells. Mol Cell Biol 19, 2425-2434. 
Tu Y, Huang Y, Zhang Y, Hua Y & Wu C (2001). A new focal adhesion protein that 
interacts with integrin-linked kinase and regulates cell adhesion and spreading. J Cell 
Biol 153, 585-598. 
Tuan TL & Nichter LS (1998). The molecular basis of keloid and hypertrophic scar 
formation. Mol Med Today 4, 19-24. 
Tziotzios C, Profyris C & Sterling J (2012). Cutaneous scarring: Pathophysiology, 
molecular mechanisms, and scar reduction therapeutics Part II. Strategies to reduce scar 
formation after dermatologic procedures. J Am Acad Dermatol 66, 13-24. 
108 
 
 
Vespa A, Darmon AJ, Turner CE, D’Souza SJ & Dagnino L (2003). Ca2+-dependent 
localization of integrin-linked kinase to cell junctions in differentiating keratinocytes. J 
Biol Chem 278, 11528-115235. 
Vespa A, D’Souza SJ & Dagnino L (2005). A novel role for integrin-linked kinase in 
epithelial sheet morphogenesis. Mol Biol Cell 16, 4084-4095. 
Vi L, de Lasa C, DiGuglielmo GM & Dagnino L (2011). Integrin-linked kinase is 
required for TGF-β1 induction of dermal myofibroblast differentiation. J Invest Dermatol 
131, 586-593. 
Wahl SM (1994). Transforming growth factor beta: the good, the bad, and the ugly. J Exp 
Med 180, 1587-1590. 
Watt FM (2002). Role of integrins in regulating epidermal adhesion, growth and 
differentiation. EMBO J 21, 3919-3926. 
Wickström SA, Lang A, Montanex E & Fässler R (2010a). The ILK/PINCH/parvin 
complex: the kinase is dead, long live the pseudokinase! EMBO J 29, 281-291. 
Wickström SA, Lange A, Hess MW, Polleux J, Spatz JP, Pfaller K, Lambacher A, Bloch 
W, Mann M, Huber LA & Fässler R (2010b). Integrin-linked kinase controls microtubule 
dynamics required for plasma membrane targeting of caveolae. Dev Cell 19, 574-588. 
Witzel F, Maddison L & Bluthgen N (2012). How scaffolds shape MAPK signaling: 
what we know and opportunities for systems approaches. Front Physiol 3, 475 
Wrana JL, Attisano L, Wieser R, Ventura F & Massagué J (1994). Mechanism of 
activation of the TGF-beta receptor. Nature 370, 341-347. 
Wu C & Dedhar S (2001). Integrin-linked kinase (ILK) and its interactors: a new 
paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling 
complexes. J Cell Biol 155, 505-510. 
Yamaji S, Suzuki A, Sugiyama Y, Koide Y, Yoshida M, Kanamori H, Mohri H, Ohno S 
& Ishigatsubo Y (2001). A novel integrin-linked kinase-binding protein, affixin, is 
involved in the early stage of cell-substrate interaction. J Cell Biol 153, 1251-1264. 
Yang L, Mao C, Teng Y, Li W, Zhang J, Cheng X, Li X, Han X, Xia Z, Deng H & Yang 
X (2005). Targeted disruption of Smad4 in mouse epidermis results in failure of hair 
follicle cycling and formation of skin tumors. Cancer Res 65, 8671-8678. 
Yang L, Li W, Wang S, Wang L, Li Y, Yang X & Peng R (2012). Smad4 disruption 
accelerates keratinocyte reepithelialisation in murine cutaneous wound repair.  Histochem 
Cell Biol 138, 573-582. 
109 
 
 
Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB & Deng D 
(1999). Targeted disruption of SMAD3 results in impaired mucosal immunity and 
diminished T cell responsiveness to TGF-beta. EMBO J 18, 1280-1291. 
Yang X, Chen L, Xu X, Li C, Huang C & Deng CX (2001). TGF-beta/Smad3 signals 
repress chondrocyte hypertrophic differentiation and are required for maintaining 
articular cartilage. J Cell Biol 153, 35-46. 
Yang Z, Mu Z, Dabovic B, Jurukovski V, Yu D, Sung J, Xiong X & Münger JS (2007). 
Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of 
TGFbeta1-null mice. J Cell Biol 176, 787-793. 
Yeung YG & Stanley ER (2009). A solution for stripping antibodies from polyvinylidene 
fluoride immunoblots for multiple reprobing. Anal Biochem 389, 89-91. 
Yu H, Bock O, Bayat A, Ferguson MW & Mrowietz U (2006). Decreased expression of 
inhibitory SMAD6 and SMAD7 in keloid scarring. J Plast Reconstr Aesthet Surg 59, 
221-229. 
Yu L, Hebert MC & Zhang YE (2002). TGF-beta receptor-activated p38 MAP kinase 
mediates Smad-independent TGF-beta responses. EMBO J 21, 3749-3759. 
Yu Q & Stamenkovic I (2000). Cell surface-localized matrix metalloproteinase-9 
proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes 
Dev 14, 163-176. 
Zambruno G, Marchisio PC, Marconi A, Vaschieri C, Melchiori A, Giannetti A & De 
Luca M (1995). Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin 
receptors and induces de novo expression of the alpha v beta 6 heterodimer in normal 
human keratinocytes: implications for wound healing. J Cell Biol 129, 853-865. 
Zervas CG, Gregory SL & Brown NH (2001). Drosophila integrin-linked kinase is 
required at sites of integrin adhesion to link the cytoskeleton to the plasma membrane. J 
Cell Biol 152, 1007-1018. 
 
110 
Appendices 
Appendix A: ILK deficiency results in decreased levels of TβRII but not TβRI 
Primary Ilkf/f dermal fibroblasts were infected with Ad-Cre (ILK-deficient) or Ad-βgal 
(ILK-expressing) at a MOI of 150. Four days after infection, lysates were prepared (100 
μg protein/sample) and processed for immunoblotting, using antibodies against TβRII, 
TβRI, and γ-tubulin, which was used to normalize for protein loading. The level of TβRI 
is comparable in ILK-expressing and ILK-deficient cells, but the level of TβRII is 
reduced in ILK-deficient fibroblasts compared to ILK-expressing fibroblasts. 
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Appendix B: ILK deficiency results in increased ubiquitination of TβRII 
Primary dermal fibroblasts were infected with Ad-Cre (ILK-deficient) or Ad-βgal (ILK-
expressing). Lysates (2 mg protein/sample) were prepared and subjected to 
immunoprecipitation with antibodies against TβRII or unrelated rabbit IgG, as control, 
followed by immunoblotting with TβRII or ubiquitin (Ub). In parallel, samples of lysates 
(20 μg protein/sample) were resolved by SDS-PAGE and transferred to a membrane, 
which was probed with antibodies against γ-tubulin, which was used to normalize for 
protein loading. The results shown are representative of experiments repeated 3 times. 
The level of TβRI is comparable in ILK-expressing and ILK-deficient cells, but the level 
of TβRII is reduced in ILK-deficient fibroblasts compared to ILK-expressing fibroblasts. 
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Appendix C: MG132 treatment restores pSMAD2 levels upon TGF-β1 stimulation 
(A) Four days after primary dermal fibroblasts were infected with Ad-Cre (ILK-deficient) 
or Ad-βgal (ILK-expressing), they were incubated in serum-free media supplemented 
with 0.1% FBS, 0.05% bovine serum albumin with MG132 (10 μM, final) or DMSO 
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(vehicle) for 8 hours and then treated with TGF-β1 or vehicle for 1 hour. Cells were lysed 
and processed for immunoblotting using antibodies against indicated proteins. GAPDH 
was used as a loading control. The level of pSMAD2 is reduced in ILK-deficient 
fibroblasts compared to ILK-expressing fibroblasts and this decrease is restored by 
MG132 treatment. (B) Densitometry of four experiments was conducted to quantify the 
relative abundance of pSMAD2 levels, which were normalized to the SMAD2/3 levels. 
Results are expressed as mean + SEM. Asterisk indicates significant difference (p<0.05, 
ANOVA, Newman-Keuls post-hoc test). There is a decrease in the level of pSMAD2 in 
ILK-deficient fibroblasts compared to ILK-expressing fibroblasts, and this is increased 
with MG132 treatment. There is no significant difference in pSMAD2 levels between 
ILK-deficient cells treated with MG132 and ILK-expressing cells treated with vehicle. 
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